

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

us-09-730-174a-5.open.ra1

TELEPHONE: 703-816-4100
 TELEFAX: 703-816-4100
 INFORMATION: 703-816-4100
 SEQUENCE CHARACTERISTICS:
 LENGTH: 30 amino acids
 TYPE: amino acids
 STRANDNESS:
 TYPE: linear
 FEATURE:
 OTHER INFORMATION: 703-816-4100, and this is the
 other information: 703-816-4100

US-09-730-174a-5

Query Match: 94.9% (Score 56) DB 3: Length 30;
 Best Local Similarity: 91.7% (Score 41, No. 0.00051)
 Matches: 11, Conservative: 1, Mismatches: 0; Gaps: 0;

QY 1 AVSDELQMINJG 12
 ID 1 SVSDELQMINJG 12

RESULT 11
 US-09-730-174a-5
 Sequence 43, Application US/09047-09
 Patent No. 6110892
 GENERAL INFORMATION:
 APPLICANT: Jean-Rome, Barbier
 APPLICANT: Neufbauer, Wilfried
 APPLICANT: Koss, Virginia
 APPLICANT: Whiffeld, James
 APPLICANT: Willink, Gordon P.
 TITLE OF INVENTION: PARATHYROID HORMONE ANALOGUES FOR THE
 TREATMENT OF STREPOBOSTS
 NUMBER OF SEQUENCES: 43
 ADDRESS: NEXEN & VANLEMAN P.C.
 STREET: 1100 No. 6110892; Gabe Rd. 8th floor
 CITY: Arlington
 STATE: VA
 COUNTRY: USA
 ZIP: 22201-4741
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 FILING DATE: 01 AUG 1997
 CLASSIFICATION: 514

TELEPHONE: 703-816-4100
 TELEFAX: 703-816-4100
 INFORMATION: 703-816-4100
 SEQUENCE CHARACTERISTICS:
 LENGTH: 30 amino acids
 TYPE: amino acids
 STRANDNESS:
 TYPE: linear
 FEATURE:
 OTHER INFORMATION: 703-816-4100, and this is the
 other information: 703-816-4100

US-09-730-174a-5

Query Match: 94.9% (Score 56) DB 3: Length 30;
 Best Local Similarity: 91.7% (Score 41, No. 0.00051)
 Matches: 11, Conservative: 1, Mismatches: 0; Gaps: 0;

QY 1 AVSDELQMINJG 12
 ID 1 SVSDELQMINJG 12

RESULT 12
 US-09-730-174a-5
 Sequence 34, Application US/09047-09
 Patent No. 6110892
 GENERAL INFORMATION:
 APPLICANT: Jean-Rome, Barbier
 APPLICANT: Neufbauer, Wilfried
 APPLICANT: Koss, Virginia
 APPLICANT: Whiffeld, James
 APPLICANT: Willink, Gordon P.
 TITLE OF INVENTION: PARATHYROID HORMONE ANALOGUES FOR THE
 TREATMENT OF STREPOBOSTS
 NUMBER OF SEQUENCES: 43
 ADDRESS: NEXEN & VANLEMAN P.C.
 STREET: 1100 No. 6110892; Gabe Rd. 8th floor
 CITY: Arlington
 STATE: VA
 COUNTRY: USA
 ZIP: 22201-4741
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 FILING DATE: 01 AUG 1997
 CLASSIFICATION: 514

TELEPHONE: 703-816-4100
 TELEFAX: 703-816-4100
 INFORMATION: 703-816-4100
 SEQUENCE CHARACTERISTICS:
 LENGTH: 30 amino acids
 TYPE: amino acids
 STRANDNESS:
 TYPE: linear
 FEATURE:
 OTHER INFORMATION: 703-816-4100, and this is the
 other information: 703-816-4100


US-09-730-174a-5

Query Match: 94.9% (Score 56) DB 3: Length 30;
 Best Local Similarity: 91.7% (Score 41, No. 0.00051)
 Matches: 11, Conservative: 1, Mismatches: 0; Gaps: 0;

QY 1 AVSDELQMINJG 12
 ID 1 SVSDELQMINJG 12

RESULT 13
 US-09-730-174a-5
 Sequence 35, Application US/09047-09
 Patent No. 6110892
 GENERAL INFORMATION:
 APPLICANT: Jean-Rome, Barbier

US-09-730-174a-5



1 APPLICATION NUMBER:
 2 FILING DATE:
 3 CLASSIFICATION:
 4 NAME: EATON, R. 556,441 B
 5 REGISTRATION NUMBER: 6263
 6 REFERENCE CHECK NUMBER: 62
 7 INFORMATIONAL NUMBER: 62
 8 TELEPHONE: (617) 47-0040
 9 TELEFAX: (617) 47-0040
 10 INFORMATION FOR SEQ ID NO: 1
 11 SEQUENCE CHARACTERISTICS:
 12 LENGTH: 40 amino acids
 13 TYPE: amino acid
 14 FEATURE:
 15 MOLECULE TYPE: protein
 16 US-09-730-174a-3

Query Match 100.0% Score 59; Pos 1; Length 40;
 Base Local Similarity 100.0%; Pos 1; Length 40;
 Matches 12; Conservation 0; Mismatches 0; Indels 0;

17 1 SVSEIOLMNLG 12
 18 1 SVSEIOLMNLG 12

RESULT 7
 US-09-730-174a-3

1 September 7, Application US-09-730-174a-3
 2 Patent No. 6110921
 3 GENERAL INFORMATION:
 4 APPLICANT: Jean-Rene, Bartol
 5 APPLICANT: Ross, Virginia
 6 APPLICANT: Whitfield, James
 7 APPLICANT: Whitfield, Gordon E.
 8 TITLE OF INVENTION: PARATHYROID HORMONE ANALOGUES FOR THE
 9 TREATMENT OF OSTEOPOROSIS
 10 NUMBER OF SEQUENCES: 4
 11 SEQUENCE NUMBER ADDRESS:
 12 ADDRESSEE: NIXON & VANORPHE P.C.
 13 STREET: 1100 No. 6110921 Ave Rd. 8th floor
 14 CITY: Arlington
 15 STATE: VA
 16 COUNTRY: USA
 17 ZIP: 22201-4741
 18 COMPUTER READABLE FORM:
 19 MEDIUM TYPE: floppy disk
 20 COMPUTER: IBM PC compatible
 21 OPERATING SYSTEM: PC-DOS/MS-DOS
 22 SOFTWARE: Patent Release # 15, Version # 1.30
 23 CURRENT APPLICATION DATA:
 24 APPLICATION NUMBER: US-09-730-174a-3
 25 FILING DATE: 01-AUG-1997
 26 CLASSIFICATION: 514
 27 PRIORITY APPLICATION DATA:
 28 APPLICATION NUMBER: 09/09-417
 29 FILING DATE: 02-AUG-1996
 30 ATTORNEY/AGENT INFORMATION:
 31 NAME: Crawford, Arthur R.
 32 REGISTRATION NUMBER: 25,42
 33 REFERENCE CHECK NUMBER: 6263
 34 TELEPHONE INFORMATION:
 35 TELEPHONE: 703-816-4000
 36 TELEFAX: 703-816-4100
 37 INFORMATION FOR SEQ ID NO: 1
 38 SEQUENCE CHARACTERISTICS:
 39 LENGTH: 40 amino acids
 40 TYPE: amino acid
 41 FEATURE:
 42 MOLECULE TYPE: protein
 43 OTHER INFORMATION:
 44 OTHER INFORMATION: has an amino group (terminus (NH2)).
 45 US-09-730-174a-3

1 APPLICATION NUMBER:
 2 FILING DATE:
 3 CLASSIFICATION:
 4 NAME: EATON, R. 556,441 B
 5 REGISTRATION NUMBER: 6263
 6 REFERENCE CHECK NUMBER: 62
 7 INFORMATIONAL NUMBER: 62
 8 TELEPHONE: (617) 47-0040
 9 TELEFAX: (617) 47-0040
 10 INFORMATION FOR SEQ ID NO: 1
 11 SEQUENCE CHARACTERISTICS:
 12 LENGTH: 40 amino acids
 13 TYPE: amino acid
 14 FEATURE:
 15 MOLECULE TYPE: protein
 16 US-09-730-174a-3

Query Match 100.0% Score 59; Pos 1; Length 40;
 Base Local Similarity 100.0%; Pos 1; Length 40;
 Matches 12; Conservation 0; Mismatches 0; Indels 0;

17 1 SVSEIOLMNLG 12
 18 1 SVSEIOLMNLG 12

RESULT 8
 US-09-730-174a-3

1 September 7, Application US-09-730-174a-3
 2 Patent No. 6110921
 3 GENERAL INFORMATION:
 4 APPLICANT: Jean-Rene, Bartol
 5 APPLICANT: Ross, Virginia
 6 APPLICANT: Whitfield, James
 7 APPLICANT: Whitfield, Gordon E.
 8 TITLE OF INVENTION: PARATHYROID HORMONE ANALOGUES FOR THE
 9 TREATMENT OF OSTEOPOROSIS
 10 NUMBER OF SEQUENCES: 4
 11 SEQUENCE NUMBER ADDRESS:
 12 ADDRESSEE: NIXON & VANORPHE P.C.
 13 STREET: 1100 No. 6110921 Ave Rd. 8th floor
 14 CITY: Arlington
 15 STATE: VA
 16 COUNTRY: USA
 17 ZIP: 22201-4741
 18 COMPUTER READABLE FORM:
 19 MEDIUM TYPE: floppy disk
 20 COMPUTER: IBM PC compatible
 21 OPERATING SYSTEM: PC-DOS/MS-DOS
 22 SOFTWARE: Patent Release # 15, Version # 1.30
 23 CURRENT APPLICATION DATA:
 24 APPLICATION NUMBER: US-09-730-174a-3
 25 FILING DATE: 01-AUG-1997
 26 CLASSIFICATION: 514
 27 PRIORITY APPLICATION DATA:
 28 APPLICATION NUMBER: 09/09-417
 29 FILING DATE: 02-AUG-1996
 30 ATTORNEY/AGENT INFORMATION:
 31 NAME: Crawford, Arthur R.
 32 REGISTRATION NUMBER: 25,42
 33 REFERENCE CHECK NUMBER: 6263
 34 TELEPHONE INFORMATION:
 35 TELEPHONE: 703-816-4000
 36 TELEFAX: 703-816-4100
 37 INFORMATION FOR SEQ ID NO: 1
 38 SEQUENCE CHARACTERISTICS:
 39 LENGTH: 40 amino acids
 40 TYPE: amino acid
 41 FEATURE:
 42 MOLECULE TYPE: protein
 43 OTHER INFORMATION:
 44 OTHER INFORMATION: has an amino group (terminus (NH2)).
 45 US-09-730-174a-3


```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```

```

QUALITY MATCH: 100.0% Score: 59, DB 1: Length: 81
Best Local Similarity: 100.0%, PID: 9.00016;
Matches: 12, Conservative: 0, Mismatches: 0, Gaps: 0

```

```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```

```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```

```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```

```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```

```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```

```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```

```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```

```

1  FILING DATE: 12 AUG 1996
2  AGENCY/OWNER: DUCHATELLE
3  NAME: GORDON, ARTHUR R.
4  REGISTRATION NO: R 1000016
5  REFERENCE/OTHER: NONE
6  TELEPHONE: 703-674-4100
7  TELEFAX: 703-674-4100
8  INFORMATION FOR SEQUENCE: N/A
9  SEQUENCE CHARACTERISTICS:
10 LENGTH: 80 amino acids
11 TYPE: amino acid
12 SCRAMBLING:
13 POLYMER: linear
14 MODIFIED: none
US-09-730-174a-3

```



```

1  TYPE=AMINOACID
2  PROCESS=CYCLIC
3  RECORD=TYPE=PROT
4  PRAIRIE
5  CIPHER=INFORMANT
6  The source of all at present
7  CIPHER=INFORMANT
8  22.01.1998. Position 26, and assigned to term a lactum, and
9  CIPHER=INFORMANT
10 The source of all at present.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

```

```

101  NAME=AMINOACID
102  PROCESS=CYCLIC
103  RECORD=TYPE=PROT
104  PRAIRIE
105  CIPHER=INFORMANT
106  The source of all at present
107  CIPHER=INFORMANT
108  22.01.1998. Position 26, and assigned to term a lactum, and
109  CIPHER=INFORMANT
110 The source of all at present.
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200

```

```

201  NAME=AMINOACID
202  PROCESS=CYCLIC
203  RECORD=TYPE=PROT
204  PRAIRIE
205  CIPHER=INFORMANT
206  The source of all at present
207  CIPHER=INFORMANT
208  22.01.1998. Position 26, and assigned to term a lactum, and
209  CIPHER=INFORMANT
210 The source of all at present.
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300

```

```

301  NAME=AMINOACID
302  PROCESS=CYCLIC
303  RECORD=TYPE=PROT
304  PRAIRIE
305  CIPHER=INFORMANT
306  The source of all at present
307  CIPHER=INFORMANT
308  22.01.1998. Position 26, and assigned to term a lactum, and
309  CIPHER=INFORMANT
310 The source of all at present.
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400

```

```

401  NAME=AMINOACID
402  PROCESS=CYCLIC
403  RECORD=TYPE=PROT
404  PRAIRIE
405  CIPHER=INFORMANT
406  The source of all at present
407  CIPHER=INFORMANT
408  22.01.1998. Position 26, and assigned to term a lactum, and
409  CIPHER=INFORMANT
410 The source of all at present.
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500

```



1 RESEARCH CENTER
2 HYPERMEDIA N
3 FRAGMENT TYPE: N
4
5 US 09-44-417A-2

Query March
Best Local Similarity: 100.0% Seq: 41; DR: 1; Length: 44
Matches: 12; Conservative: 0; Mismatches: 0; Gaps: 0;

27 1 AVSELEPHENIN 12
28 1 AVSELEPHENIN 12

RESULT 10
US 09-44-417A-2
Sequence 2, Application US/0440417A
Patent No. 5807923

GENERAL INFORMATION:
APPLICANT: VICKERY, Brian L.
TITLE OF INVENTION: METHOD FOR THE PREPARATION OF CORTICOSTEROID
TITLE OF INVENTION: METHOD FOR THE PREPARATION OF CORTICOSTEROID
NUMBER OF SEQUENCES: 96

REFERENCE/SEQUENCE NUMBER: 296; 424
CURRENT APPLICATION DATA:
ADDRESSER: Patent Dept., Synex (U.S.A.), Inc.
STREET: 4401 Hillview Ave.
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94303

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1, Version #1.25

APPLICANT NUMBER: US/0440417A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: Schmonsoes, William
REGISTRATION NUMBER: 31,796
REFERENCE/SEQUENCE NUMBER: 296; 424

TELEPHONE: 415-855-6593
TELEFAX: 415-496-3529
E-MAIL FOR SEQ ID NO: 1

SEQUENCE CHARACTERISTICS:
LENGTH: 44 amino acids
TYPE: amino acid
PRO-LOGY: linear

SEQUENCE TYPE: N-terminal
SEQUENCE: 447-522-2

2967 Match, 100.0%; Score 61; DR 2; Length 44;
Best Local Similarity: 100.0%; Seq: 41; DR: 1; Length 44;
Matches: 12; Conservative: 0; Mismatches: 0; Gaps: 0;

QY 1 AVSELEPHENIN 12
24 1 AVSELEPHENIN 12

US 09-44-417A-2
Sequence 2, Application US/0440417A
Patent No. 5807923

GENERAL INFORMATION:
APPLICANT: Kristiansky, John L.
TITLE OF INVENTION: PARATHYROID HORMONE RELATED PEPTIDE: SYNTHESIS AND USE
TITLE OF INVENTION: PARATHYROID HORMONE RELATED PEPTIDE: SYNTHESIS AND USE
NUMBER OF SEQUENCES: 86

REFERENCE/SEQUENCE ADDRESS:
ADDRESSER: Patent Dept., Synex (U.S.A.), Inc.
STREET: 4401 Hillview Ave.
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94303

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1, Version #1.25

APPLICANT NUMBER: US/0440417A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: Schmonsoes, William
REGISTRATION NUMBER: 31,796
REFERENCE/SEQUENCE NUMBER: 296; 424

TELEPHONE: 415-855-6593
TELEFAX: 415-496-3529
E-MAIL FOR SEQ ID NO: 1

SEQUENCE CHARACTERISTICS:
LENGTH: 44 amino acids
TYPE: amino acid
PRO-LOGY: linear

1 RESEARCH CENTER
2 HYPERMEDIA N
3 FRAGMENT TYPE: N
4
5 US 09-44-417A-2

Query March
Best Local Similarity: 100.0% Seq: 41; DR: 1; Length: 44
Matches: 12; Conservative: 0; Mismatches: 0; Gaps: 0;

27 1 AVSELEPHENIN 12
28 1 AVSELEPHENIN 12

RESULT 10
US 09-44-417A-2
Sequence 2, Application US/0440417A
Patent No. 5807923

GENERAL INFORMATION:
APPLICANT: VICKERY, Brian L.
TITLE OF INVENTION: METHOD FOR THE PREPARATION OF CORTICOSTEROID
TITLE OF INVENTION: METHOD FOR THE PREPARATION OF CORTICOSTEROID
NUMBER OF SEQUENCES: 96

REFERENCE/SEQUENCE NUMBER: 296; 424
CURRENT APPLICATION DATA:
ADDRESSER: Patent Dept., Synex (U.S.A.), Inc.
STREET: 4401 Hillview Ave.
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94303

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1, Version #1.25

APPLICANT NUMBER: US/0440417A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: Schmonsoes, William
REGISTRATION NUMBER: 31,796
REFERENCE/SEQUENCE NUMBER: 296; 424

TELEPHONE: 415-855-6593
TELEFAX: 415-496-3529
E-MAIL FOR SEQ ID NO: 1

SEQUENCE CHARACTERISTICS:
LENGTH: 44 amino acids
TYPE: amino acid
PRO-LOGY: linear

SEQUENCE TYPE: N-terminal
SEQUENCE: 447-522-2

2967 Match, 100.0%; Score 61; DR 2; Length 44;
Best Local Similarity: 100.0%; Seq: 41; DR: 1; Length 44;
Matches: 12; Conservative: 0; Mismatches: 0; Gaps: 0;

QY 1 AVSELEPHENIN 12
24 1 AVSELEPHENIN 12

US 09-44-417A-2
Sequence 2, Application US/0440417A
Patent No. 5807923

GENERAL INFORMATION:
APPLICANT: Kristiansky, John L.
TITLE OF INVENTION: PARATHYROID HORMONE RELATED PEPTIDE: SYNTHESIS AND USE
TITLE OF INVENTION: PARATHYROID HORMONE RELATED PEPTIDE: SYNTHESIS AND USE
NUMBER OF SEQUENCES: 86

REFERENCE/SEQUENCE ADDRESS:
ADDRESSER: Patent Dept., Synex (U.S.A.), Inc.
STREET: 4401 Hillview Ave.
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94303

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1, Version #1.25

APPLICANT NUMBER: US/0440417A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: Schmonsoes, William
REGISTRATION NUMBER: 31,796
REFERENCE/SEQUENCE NUMBER: 296; 424

TELEPHONE: 415-855-6593
TELEFAX: 415-496-3529
E-MAIL FOR SEQ ID NO: 1

SEQUENCE CHARACTERISTICS:
LENGTH: 44 amino acids
TYPE: amino acid
PRO-LOGY: linear

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000



1. PHOSPHORYLATION OF PHOSPHOLIPIDS BY THE ENZYME, "PHOSPHOLIPASE D," FROM *STREPTOCOCCUS* 1972, 1973, 1974, 1975, 1976, 1977, 1978, 1979, 1980, 1981, 1982, 1983, 1984, 1985, 1986, 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646,

The Swiss Federal Patent Office has produced a new collaboration between the Swiss Patent Office, the German Patent Office and the French Patent Office and their respective authorities on the basis of the Paris Convention for the Protection of Industrial Property. The Swiss Patent Office has been designated as the central office for the purpose of the Convention. The Swiss Patent Office has been designated as the central office for the purpose of the Convention. The Swiss Patent Office has been designated as the central office for the purpose of the Convention.

[illegible][illegible]

```

Query Match Similarity 62.5% Score 36 DB 1 Length 1074;
Best local Similarity 54.5% Pct. NO. 15;
Matches 6, Conservative 0 Mismatches 1, Indels 0 Gaps 0;
C1 2 VSEIQPMHNL 12
      1 1 1 1 1 1 1
      2 36 VSEIQPMHNL 218

```

[illegible]

Mycoplasma pneumoniae,
bacterial Firmicutes, Bacilli:Clostridium group; Molluscus;
Mycobacterium; Mycoplasma
S-M-I TaxID 2104;
111
SHOENKE FROM N.A.
STRAIN A/C-79342 / ML29-
MUSKIE 6715805; MLMed 8349042
Dromedary; H. Hilbert H. Grosse H. Pittl E., Li B.-C.,
Hilbert H.;
incomplete sequence analysis - the genome of the bacterium *Mycoplasma*
pneumoniae, #,
Nucleic Acids Res. 24:4420-4434(1996).
I FUNCTION, THE M AND S SUBUNIT TOGETHER FORM A METHYLTRANSFERASE
(MASE) THAT METHYLATES THE ADENINE RESIDUES IN COMPLEMENTARY
STRANDS OF MPARITE DNA REPLICATION SEQUENCE. SUBUNIT S DICTATES
DNA SEQUENCES SPECIFICITY (BY SIMILARITY)
-1- SHUNT: THE TYPE I RESTRICTION & MODIFICATION SYSTEM IS COMPOSED
OF THREE POLYPEPTIDES S-R AND S' (BY SIMILARITY).
-1- DOMAIN CONTAINS TWO RNA RECOGNITION DOMAINS, EACH SPECIFYING
RECOGNITION OF ONE OF THE TWO DEFINED COMPONENTS OF THE TARGET
SEQUENCE (BY SIMILARITY)
I SIMILARITY, BELONG TO THE I FUNCTION SYSTEM S METHYLASE
FAMILY

the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed, false or for commercial purposes.

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

XX polypeptide and the present invention is also suitable for use as a PTH as a
XX natural product of a natural source. The PTH polypeptide is derived from
XX are useful for treatment and diagnosis characterized by a decrease in bone
XX mass, such as osteoporosis and postmenopausal osteoporosis. The
XX polypeptides are also useful for determining rates of bone reformation,
XX bone resorption and/or bone remodeling, by administering the polypeptide
XX to the patient and determining the uptake of the polypeptide into the bone,
XX and/or bone loss. The decrease in amount of the polypeptide administered
XX by providing 1 to 5, but not 100,000, copies of the polypeptide, also be
XX polypeptide, in vivo, the level of osteoporosis and osteoporosis can also be
XX increased in a mammalian cell, but not PTH 1 receptors, by administering the
XX polypeptide with a suitable amount of PTH 1 polypeptides.

XX Sequence: 17 AA

Query Match: 100.0%; Pos: 59; DB: 22; Length: 14;
Best Local Similarity: 100.0%; Pos: 59; DB: 22; Length: 14;
Mat. Pos: 12; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;

QY 1 SVSEIQLMINL 12

1 11111111

12 1 SVSEIQLMINL 12

1 11111111

13 1 SVSEIQLMINL 12

1 11111111

14 1 SVSEIQLMINL 12

1 11111111

15 1 SVSEIQLMINL 12

1 11111111

16 1 SVSEIQLMINL 12

1 11111111

17 1 SVSEIQLMINL 12

1 11111111

18 1 SVSEIQLMINL 12

1 11111111

19 1 SVSEIQLMINL 12

1 11111111

20 1 SVSEIQLMINL 12

1 11111111

21 1 SVSEIQLMINL 12

1 11111111

22 1 SVSEIQLMINL 12

1 11111111

23 1 SVSEIQLMINL 12

1 11111111

24 1 SVSEIQLMINL 12

1 11111111

25 1 SVSEIQLMINL 12

1 11111111

26 1 SVSEIQLMINL 12

1 11111111

27 1 SVSEIQLMINL 12

1 11111111

28 1 SVSEIQLMINL 12

1 11111111

29 1 SVSEIQLMINL 12

1 11111111

30 1 SVSEIQLMINL 12

1 11111111

31 1 SVSEIQLMINL 12

1 11111111

32 1 SVSEIQLMINL 12

1 11111111

33 1 SVSEIQLMINL 12

1 11111111

Query Match: 100.0%; Pos: 59; DB: 22; Length: 14;
Best Local Similarity: 100.0%; Pos: 59; DB: 22; Length: 14;
Mat. Pos: 12; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;

QY 1 SVSEIQLMINL 12

1 11111111

13 1 SVSEIQLMINL 12

1 11111111

14 1 SVSEIQLMINL 12

1 11111111

15 1 SVSEIQLMINL 12

1 11111111

16 1 SVSEIQLMINL 12

1 11111111

17 1 SVSEIQLMINL 12

1 11111111

18 1 SVSEIQLMINL 12

1 11111111

19 1 SVSEIQLMINL 12

1 11111111

20 1 SVSEIQLMINL 12

1 11111111

21 1 SVSEIQLMINL 12

1 11111111

22 1 SVSEIQLMINL 12

1 11111111

23 1 SVSEIQLMINL 12

1 11111111

24 1 SVSEIQLMINL 12

1 11111111

25 1 SVSEIQLMINL 12

1 11111111

26 1 SVSEIQLMINL 12

1 11111111

27 1 SVSEIQLMINL 12

1 11111111

28 1 SVSEIQLMINL 12

1 11111111

29 1 SVSEIQLMINL 12

1 11111111

30 1 SVSEIQLMINL 12

1 11111111

31 1 SVSEIQLMINL 12

1 11111111

32 1 SVSEIQLMINL 12

1 11111111

33 1 SVSEIQLMINL 12

1 11111111

34 1 SVSEIQLMINL 12

1 11111111

35 1 SVSEIQLMINL 12

1 11111111

36 1 SVSEIQLMINL 12

1 11111111

Query Match: 100.0%; Pos: 59; DB: 22; Length: 14;
Best Local Similarity: 100.0%; Pos: 59; DB: 22; Length: 14;
Mat. Pos: 12; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;

QY 1 SVSEIQLMINL 12

1 11111111

13 1 SVSEIQLMINL 12

1 11111111

14 1 SVSEIQLMINL 12

1 11111111

15 1 SVSEIQLMINL 12

1 11111111

16 1 SVSEIQLMINL 12

1 11111111

17 1 SVSEIQLMINL 12

1 11111111

18 1 SVSEIQLMINL 12

1 11111111

19 1 SVSEIQLMINL 12

1 11111111

20 1 SVSEIQLMINL 12

1 11111111

21 1 SVSEIQLMINL 12

1 11111111

22 1 SVSEIQLMINL 12

1 11111111

23 1 SVSEIQLMINL 12

1 11111111

24 1 SVSEIQLMINL 12

1 11111111

25 1 SVSEIQLMINL 12

1 11111111

26 1 SVSEIQLMINL 12

1 11111111

27 1 SVSEIQLMINL 12

1 11111111

28 1 SVSEIQLMINL 12

1 11111111

29 1 SVSEIQLMINL 12

1 11111111

30 1 SVSEIQLMINL 12

1 11111111

31 1 SVSEIQLMINL 12

1 11111111

32 1 SVSEIQLMINL 12

1 11111111

33 1 SVSEIQLMINL 12

1 11111111

34 1 SVSEIQLMINL 12

1 11111111

35 1 SVSEIQLMINL 12

1 11111111

36 1 SVSEIQLMINL 12

1 11111111

Query Match: 100.0%; Pos: 59; DB: 22; Length: 14;
Best Local Similarity: 100.0%; Pos: 59; DB: 22; Length: 14;
Mat. Pos: 12; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;

QY 1 SVSEIQLMINL 12

1 11111111

13 1 SVSEIQLMINL 12

1 11111111

14 1 SVSEIQLMINL 12

1 11111111

15 1 SVSEIQLMINL 12

1 11111111

16 1 SVSEIQLMINL 12

1 11111111

17 1 SVSEIQLMINL 12

1 11111111

18 1 SVSEIQLMINL 12

1 11111111

19 1 SVSEIQLMINL 12

1 11111111

20 1 SVSEIQLMINL 12

1 11111111

21 1 SVSEIQLMINL 12

1 11111111

22 1 SVSEIQLMINL 12

1 11111111

23 1 SVSEIQLMINL 12

1 11111111

24 1 SVSEIQLMINL 12

1 11111111

25 1 SVSEIQLMINL 12

1 11111111

26 1 SVSEIQLMINL 12

1 11111111

27 1 SVSEIQLMINL 12

1 11111111

28 1 SVSEIQLMINL 12

1 11111111

29 1 SVSEIQLMINL 12

1 11111111

30 1 SVSEIQLMINL 12

1 11111111

31 1 SVSEIQLMINL 12

1 11111111

32 1 SVSEIQLMINL 12

1 11111111

33 1 SVSEIQLMINL 12

1 11111111

34 1 SVSEIQLMINL 12

1 11111111

35 1 SVSEIQLMINL 12

1 11111111

36 1 SVSEIQLMINL 12

1 11111111

Query Match: 100.0%; Pos: 59; DB: 22; Length: 14;
Best Local Similarity: 100.0%; Pos: 59; DB: 22; Length: 14;
Mat. Pos: 12; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;

QY 1 SVSEIQLMINL 12

1 11111111

13 1 SVSEIQLMINL 12

1 11111111

14 1 SVSEIQLMINL 12

1 11111111

15 1 SVSEIQLMINL 12

1 11111111

16 1 SVSEIQLMINL 12

1 11111111

17 1 SVSEIQLMINL 12

1 11111111

18 1 SVSEIQLMINL 12

1 11111111

19 1 SVSEIQLMINL 12

1 11111111

20 1 SVSEIQLMINL 12

1 11111111

21 1 SVSEIQLMINL 12

1 11111111

22 1 SVSEIQLMINL 12

1 11111111

23 1 SVSEIQLMINL 12

1 11111111

24 1 SVSEIQLMINL 12

1 11111111

25 1 SVSEIQLMINL 12

1 11111111

26 1 SVSEIQLMINL 12

1 11111111

27 1 SVSEIQLMINL 12

1 11111111

28 1 SVSEIQLMINL 12

1 11111111

29 1 SVSEIQLMINL 12

1 11111111

30 1 SV

CC myeloma and epidermal cancers of the head, neck and extremities. The present sequence is a PTH peptide, with a Ser residue at position 1 and a Glu residue at position 19. The Ser residue improves downstream signal and via phospholipase C (PLC), whereas the Glu residue reduces PLC signal and binds to the PTH receptor. The Glu residue at position 19 has been observed in the PTH and human PTH and so may be used as a PTH receptor antagonist in the treatment of the above mentioned disorders and their complications.

XX
SQ Sequence 28 AA:

Query Match: 100.0% Score 59; DB 21; Length 28;
AA881074 Similarity 100.0% Id. No. 0.00037;
Matches 12; Conserved 12; Gaps 0;

QY 1 SVSEIQLMHNLG 12
IIIIIIIIII
II 1 svseqlmhnlq 12

RESULT 14
AA881074
ID AA881074 standard; peptide; 28 AA

XX AA881074;
XX 26-JUN-2001 (first entry);

XX Human parathyroid hormone analog; SEQ ID 1;
XX Parathyroid hormone (PTH); blood calcium level regulator; osteopathic;
XX vulnary; bone growth; bone healing; osteoporosis; fracture; human.

XX Homo sapiens.
XX Synthetic.

XX Key: Location/Qualif
XX Modified-site 22 /note= "Forms a beta lactam ring with Asp at position 26"

XX Modified-site 26 /note= "Forms a beta lactam ring with Lys at position 22"

XX Modified-site 28 /note= "C-terminal amide"

XX W20010424-A2
XX 29 MAR 2001;
XX 21-SEP-2000; 2000W0-CA01094;
XX 22-SEP-1999; 99US-0406833;

XX (PANA) NAT RES COUNCIL CANADA;
XX Barber J, Morley P, Whitham J, Willick GE;
XX WPI; 2001 33081/22;

XX New human parathyroid hormone (PTH) analog useful for stimulating bone growth for restoring bone, for promotion of bone healing, and for treating osteoporosis and normal fractures

XX Claim 16; Fig 6; 34pp; English;

XX Parathyroid hormone (PTH) is a major regulator of blood calcium levels, this invention relates to hPTH analogues, or their salts. Use of the analogues results in osteoparic and vulnary activity. The hPTH analogues are useful for treating a warm-blooded animal for stimulating bone growth, for restoring bone, and for the promotion of bone healing during the treatment of osteoporosis and normal fractures. The present sequence represents an analogue of human parathyroid hormone.

XX Query Match: 100.0% Score 59; DB 21; Length 28;
XX Best Local Similarity 100.0% Id. No. 0.00037;

SC Sequence 28 AA;

Query Match: 100.0% Score 59; DB 22; Length 28;
Best Local Similarity 100.0% Id. No. 0.00037;
Matches 12; Conserved 12; Gaps 0;

QY 1 SVSEIQLMHNLG 12
IIIIIIIIII
II 1 svseqlmhnlq 12

RESULT 14
AA881078
ID AA881078 standard; peptide; 28 AA

XX AA881078;
XX 26-JUN-2001 (first entry);

XX Human parathyroid hormone analog; SEQ ID 6;
XX Parathyroid hormone (PTH); blood calcium level regulator; osteopathic;
XX vulnary; bone growth; bone healing; osteoporosis; fracture; human.

XX Homo sapiens.
XX Synthetic.

XX Key: Location/Qualif
XX Modified-site 13 /note= "Forms a beta lactam ring with Glu at position 17"

XX Modified-site 17 /note= "Forms a beta lactam ring with Lys at position 13"

XX Modified-site 22 /note= "Forms a beta lactam ring with Lys at position 26"

XX Modified-site 26 /note= "C-terminal amide"

XX W20010424-A2
XX 29 MAR 2001;
XX 21-SEP-2000; 2000W0-CA01094;
XX 22-SEP-1999; 99US-0406833;

XX (PANA) NAT RES COUNCIL CANADA;
XX Barber J, Morley P, Whitham J, Willick GE;
XX WPI; 2001 33081/22;

XX New human parathyroid hormone (PTH) analog useful for stimulating bone growth for restoring bone, for promotion of bone healing, and for treating osteoporosis and normal fractures

XX Claim 16; Fig 6; 34pp; English;

XX Parathyroid hormone (PTH) is a major regulator of blood calcium levels, this invention relates to hPTH analogues, or their salts. Use of the analogues results in osteoparic and vulnary activity. The hPTH analogues are useful for treating a warm-blooded animal for stimulating bone growth, for restoring bone, and for the promotion of bone healing during the treatment of osteoporosis and normal fractures. The present sequence represents an analogue of human parathyroid hormone.

XX Query Match: 100.0% Score 59; DB 22; Length 28;
XX Best Local Similarity 100.0% Id. No. 0.00037;

10 000000Z SEP 02 000000Z
11 000000Z
12 000000Z
13 000000Z
14 000000Z
15 000000Z
16 000000Z
17 000000Z
18 000000Z
19 000000Z
20 000000Z
21 000000Z
22 000000Z
23 000000Z
24 000000Z
25 000000Z
26 000000Z
27 000000Z
28 000000Z
29 000000Z
30 000000Z
31 000000Z
32 000000Z
33 000000Z
34 000000Z
35 000000Z
36 000000Z
37 000000Z
38 000000Z
39 000000Z
40 000000Z
41 000000Z
42 000000Z
43 000000Z
44 000000Z
45 000000Z
46 000000Z
47 000000Z
48 000000Z
49 000000Z
50 000000Z
51 000000Z
52 000000Z
53 000000Z
54 000000Z
55 000000Z
56 000000Z
57 000000Z
58 000000Z
59 000000Z
60 000000Z
61 000000Z
62 000000Z
63 000000Z
64 000000Z
65 000000Z
66 000000Z
67 000000Z
68 000000Z
69 000000Z
70 000000Z
71 000000Z
72 000000Z
73 000000Z
74 000000Z
75 000000Z
76 000000Z
77 000000Z
78 000000Z
79 000000Z
80 000000Z
81 000000Z
82 000000Z
83 000000Z
84 000000Z
85 000000Z
86 000000Z
87 000000Z
88 000000Z
89 000000Z
90 000000Z
91 000000Z
92 000000Z
93 000000Z
94 000000Z
95 000000Z
96 000000Z
97 000000Z
98 000000Z
99 000000Z
100 000000Z

10 000000Z SEP 02 000000Z
11 000000Z
12 000000Z
13 000000Z
14 000000Z
15 000000Z
16 000000Z
17 000000Z
18 000000Z
19 000000Z
20 000000Z
21 000000Z
22 000000Z
23 000000Z
24 000000Z
25 000000Z
26 000000Z
27 000000Z
28 000000Z
29 000000Z
30 000000Z
31 000000Z
32 000000Z
33 000000Z
34 000000Z
35 000000Z
36 000000Z
37 000000Z
38 000000Z
39 000000Z
40 000000Z
41 000000Z
42 000000Z
43 000000Z
44 000000Z
45 000000Z
46 000000Z
47 000000Z
48 000000Z
49 000000Z
50 000000Z
51 000000Z
52 000000Z
53 000000Z
54 000000Z
55 000000Z
56 000000Z
57 000000Z
58 000000Z
59 000000Z
60 000000Z
61 000000Z
62 000000Z
63 000000Z
64 000000Z
65 000000Z
66 000000Z
67 000000Z
68 000000Z
69 000000Z
70 000000Z
71 000000Z
72 000000Z
73 000000Z
74 000000Z
75 000000Z
76 000000Z
77 000000Z
78 000000Z
79 000000Z
80 000000Z
81 000000Z
82 000000Z
83 000000Z
84 000000Z
85 000000Z
86 000000Z
87 000000Z
88 000000Z
89 000000Z
90 000000Z
91 000000Z
92 000000Z
93 000000Z
94 000000Z
95 000000Z
96 000000Z
97 000000Z
98 000000Z
99 000000Z
100 000000Z

DP PROSITE: ISG247 (PROSITE) 62.0% Score 68 DB 10; Length 100
 DI PROSITE: ISG247 (PROSITE) 62.0% Score 68 DB 10; Length 100
 FI NON-ITER 1 1
 FI NON-ITER 464 464
 FI NON-ITER 464 464

Query Match 62.0% Score 68 DB 10; Length 100
 Best Local Similarity 62.0% Score 68 DB 10; Length 100
 Matches 5; Conserved 4; Gaps 0

QY 5 USEPHEM12

DI 162 VYMER169

RESULT 13

QY 5 USEPHEM12

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI 162 VYMER169

DI PROSITE: ISG247 (PROSITE) 62.0% Score 68 DB 10; Length 100

DI PROSITE: ISG247 (PROSITE) 62.0% Score 68 DB 10; Length 100

FI NON-ITER 1 1

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

FI NON-ITER 464 464

us-09-730-174a-3.open.rpr

us-09-730-174a-3.open.rpr
 Title: us-09-730-174a-3
 Sequence: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

us-09-730-174a-3.open.rpr

us-09-730-174a-3.open.rpr
 Title: us-09-730-174a-3
 Sequence: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

us-09-730-174a-3.open.rpr
 Title: us-09-730-174a-3
 Sequence: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

us-09-730-174a-3.open.rpr
 Title: us-09-730-174a-3
 Sequence: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

us-09-730-174a-3.open.rpr
 Title: us-09-730-174a-3
 Sequence: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

us-09-730-174a-3.open.rpr
 Title: us-09-730-174a-3
 Sequence: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

us-09-730-174a-3.open.rpr
 Title: us-09-730-174a-3
 Sequence: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12
 Search: 1 SVSP, MINUS 12

Annotations: 29/4
 Classification: parathyroid hormone-related hormone homology
 P130-64/familial parathyroid hormone-related protein

Query Match 44.9% Score 963 DB 25 Length 113
 Best Local Similarity 44.9% Score 963 DB 25 Length 113
 Matches 113 Conservative 0 Mismatches 0 Gaps 0

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

QV 1 SVSEIQLMHNLG 44

14 AVSEIQLMHNLG 44

RESIDUE 4

AVSEIQLMHNLG 44

FT SIGNAL 1 24 10 INITIAL
 FT PROPER 25 34 BY SENSITIVITY
 FT CHAIN 37 47 FALSIFIED BEARING FOR OTHER POSITION
 SO SENSITIVE 177 AA 11290 MW 112901250166A200 1000

Query Match 35 34 Score 45; DB 1; Length 177
 Best Load Similarity 38 34; Prod No 9, 4;
 Matches 7; Counsel 0; No 0; Matches 2; Days 0;

27 1 SVSCLUBHUNG
 47 47 AVSCLUBHUNG

Search Comp 0.00; Sep 21 2002 13:30:29
 Job Time: 687 sec

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text outlines various methods for organizing and storing data, including digital databases and physical filing systems. It also mentions the need for regular audits and reviews to ensure the integrity of the information.

2. The second part of the document focuses on the role of communication in achieving organizational goals. It highlights the importance of clear and concise communication, both internally and externally. The text provides guidelines for effective communication, such as using appropriate language, listening actively, and providing feedback. It also discusses the benefits of open communication and how it can foster a collaborative work environment.

3. The third part of the document addresses the challenges of managing resources and personnel. It discusses the importance of proper planning and allocation of resources to ensure that the organization can meet its objectives. The text also touches upon the need for effective personnel management, including recruitment, training, and performance evaluation. It emphasizes the importance of maintaining a motivated and skilled workforce.

4. The fourth part of the document discusses the importance of innovation and creativity in driving organizational growth. It encourages the organization to embrace new ideas and technologies, and to foster a culture of innovation. The text provides examples of successful innovation strategies and discusses the role of leadership in promoting a culture of creativity. It also mentions the importance of protecting intellectual property and encouraging collaboration between different departments.

5. The fifth part of the document discusses the importance of risk management and compliance. It outlines the various risks that an organization may face, such as financial risks, operational risks, and legal risks. The text provides guidelines for identifying, assessing, and mitigating these risks. It also discusses the importance of staying up-to-date with relevant laws and regulations, and ensuring that the organization is in full compliance with all applicable requirements.

6. The sixth part of the document discusses the importance of sustainability and social responsibility. It outlines the various ways in which an organization can contribute to society, such as through environmental protection, social welfare, and ethical practices. The text provides guidelines for developing and implementing a sustainable business strategy, and discusses the benefits of doing so. It also mentions the importance of reporting on the organization's sustainability performance to stakeholders.

7. The seventh part of the document discusses the importance of continuous improvement and learning. It outlines the various methods for identifying areas for improvement, such as through customer feedback, employee suggestions, and performance reviews. The text provides guidelines for implementing improvement initiatives, and discusses the importance of monitoring and evaluating the results. It also mentions the importance of fostering a culture of learning and development, and encouraging employees to take ownership of their own growth.

8. The eighth part of the document discusses the importance of strategic planning and vision. It outlines the various steps involved in developing a strategic plan, such as identifying the organization's mission and vision, assessing the current situation, and setting goals and objectives. The text provides guidelines for implementing the strategic plan, and discusses the importance of staying focused on the long-term vision. It also mentions the importance of reviewing and updating the strategic plan regularly to reflect changes in the organization and its environment.

9. The ninth part of the document discusses the importance of financial management and budgeting. It outlines the various aspects of financial management, such as budgeting, accounting, and financial reporting. The text provides guidelines for developing and implementing a sound financial strategy, and discusses the importance of maintaining accurate financial records. It also mentions the importance of seeking professional advice when needed, and ensuring that the organization is in good financial health.

10. The tenth part of the document discusses the importance of leadership and management. It outlines the various roles and responsibilities of leaders and managers, and provides guidelines for effective leadership and management. The text discusses the importance of setting a clear vision and direction, and inspiring and motivating the team. It also mentions the importance of being a role model, and demonstrating the values and behaviors that the organization expects of its employees.

[illegible]

1 TITLE: 415-440-529
 2 TELEFAX: 415-440-529
 3 INFORMATION FOR SEQ ID NO: 1
 4 SEQUENCE CHARACTERISTICS:
 5 LENGTH: 44 amino acids
 6 TYPE: amino acid
 7 TOPOLOGY: linear
 8 MOLECULE TYPE: protein
 9 HYDROPHILIC: N
 10 FRAGMENT TYPE: N-terminal
 11 US-09 448 105-2

Query Match: 95.11% (Seq ID: 1011) Length: 44
 Best Local Similarity: 91.7% (Seq ID: 0.00014)
 Matches: 11; Conservative: 0; Indels: 0; Gaps: 0;

1 1 SVSEIOPMHNLG 12

1b 1 AVSEIOPMHNLG 12

RESULT 5

US-09 448 105-2

Sequence: Application US/084841

Patent No. 5717062

GENERAL INFORMATION:

APPLICANT: Rosenblatt, Michael

INVENTOR: Rosenblatt, Michael

ADDRESS: Fish & Richards, P.C.

APPLICANT: Fish & Richards, P.C.

ADDRESS: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: USA

ZIP: 02110-2804

COMPIER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPIER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: 07/397891

FILE NUMBER: 617/542-5070

CLASSIFICATION: 530

ATTORNEY/AGENT INFORMATION:

NAME: Fish & Richards, P.C.

REGISTRATION NUMBER: 04,065

REFERENCE/EXCERPT NUMBER: 1/1 7/1 2001

OTHER INFORMATION: INFORMATION

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 1

SEQUENCE CHARACTERISTICS:

LENGTH: 44 amino acids

TYPE: amino acid

GLYCANATION: not relevant

TOPOLOGY: linear

MOLECULE TYPE: protein

FEATURE:

OTHER INFORMATION: The side chains of lys at

positions 1 and 2 are linked by an amide b

and this sequence has an amide C-terminus (i.e., CONH2).

US-09 448 105-2

Query Match: 95.11% (Seq ID: 1011) Length: 44

Best Local Similarity: 91.7% (Seq ID: 0.00014)

Matches: 11; Conservative: 0; Indels: 0; Gaps: 0;

1 1 SVSEIOPMHNLG 12

1b 1 AVSEIOPMHNLG 12

RESULT 7

US-09 448 105-2

Sequence: Application US/084841

Patent No. 5717062

GENERAL INFORMATION:

APPLICANT: Rosenblatt, Michael

INVENTOR: Rosenblatt, Michael

ADDRESS: Fish & Richards, P.C.

APPLICANT: Fish & Richards, P.C.

ADDRESS: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: USA

ZIP: 02110-2804

COMPIER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPIER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: 07/397891

FILE NUMBER: 617/542-5070

CLASSIFICATION: 530

ATTORNEY/AGENT INFORMATION:

NAME: Fish & Richards, P.C.

REGISTRATION NUMBER: 04,065

REFERENCE/EXCERPT NUMBER: 1/1 7/1 2001

OTHER INFORMATION: INFORMATION

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 1

SEQUENCE CHARACTERISTICS:

LENGTH: 44 amino acids

TYPE: amino acid

GLYCANATION: not relevant

TOPOLOGY: linear

MOLECULE TYPE: protein

FEATURE:

OTHER INFORMATION: The side chains of lys at

positions 1 and 2 are linked by an amide b

and this sequence has an amide C-terminus (i.e., CONH2).

US-09 448 105-2

Query Match: 95.11% (Seq ID: 1011) Length: 44

Best Local Similarity: 91.7% (Seq ID: 0.00014)

Matches: 11; Conservative: 0; Indels: 0; Gaps: 0;

1 1 SVSEIOPMHNLG 12

1b 1 AVSEIOPMHNLG 12

1 MEDIUM TYPE: 111 disk
2 HYPOTHEICAL: No
3 FRAGMENT TYPE: No
4 US-09-44-017A-2

Query Match 95.14; Score 58; DB 1; Length 44
Best Local Similarity 94.94; Gap 0.00013
Matches 11; Conservative 1; Misses 0; Gaps 0

Q7 1 AVSECTEMINUS 12
DB 1 AVSECTEMINUS 12

RESULT 10
US-09-44-017A-2
Sequence 2: Application US/044047A
Patent No. 58 7424

1 GENERAL INFORMATION:
2 APPLICANT: VICKERY, Brian H
3 TITLE OF INVENTION: METHOD FOR TREATMENT OF OSTEOPOROSIS
4 TITLE OF INVENTION: METHOD FOR TREATMENT OF OSTEOPOROSIS
5 NUMBER OF SEQUENCES: 86
6 CORRESPONDENCE ADDRESS:
7 ADDRESSEE: Patent Dept., Vickery (U.S.A.), Inc.
8 STREET: 4401 Hillview Ave.
9 CITY: Palo Alto
10 STATE: CA
11 COUNTRY: USA
12 ZIP: 94304
13 MEDIUM READABLE FORM:
14 MEDIUM TYPE: floppy disk
15 MEDIUM: IBM PC compatible
16 SOFTWARE: Patent Release #1.0, Version #1.25
17 CURRENT APPLICATION DATA:
18 APPLICATION NUMBER: 07 JUN 1995
19 FILING DATE: 07 JUN 1995
20 CLASSIFICATION: 435

21 ATTORNEY/AGENT INFORMATION:
22 NAME: Schmoos, William
23 REGISTRATION NUMBER: 51746
24 REFERENCE/SEQUENCE NUMBER: 076-012

25 TELEPHONE: 415-495-6593
26 TELEFAX: 415-495-6529
27 IN-EMAIL: No
28 SEQUENCE CHARACTERISTICS:
29 LENGTH: 44 amino acids
30 TYPE: amino acid
31 LOCATION: Linear

32 MEDIUM TYPE: floppy
33 HYPOTHEICAL: No
34 FRAGMENT TYPE: No
35 US-09-44-017A-2

Query Match 95.14; Score 58; DB 1; Length 44
Best Local Similarity 94.94; Gap 0.00013
Matches 11; Conservative 1; Misses 0; Gaps 0

Q7 1 AVSECTEMINUS 12
DB 1 AVSECTEMINUS 12

RESULT 11
US-09-44-017A-2
Sequence 2: Application US/044702A
Patent No. 58 7424

1 GENERAL INFORMATION:
2 APPLICANT: VICKERY, Brian H

1 TITLE OF INVENTION: METHOD FOR TREATMENT OF OSTEOPOROSIS
2 TITLE OF INVENTION: METHOD FOR TREATMENT OF OSTEOPOROSIS
3 NUMBER OF SEQUENCES: 86
4 CORRESPONDENCE ADDRESS:
5 ADDRESSEE: Patent Dept., Vickery (U.S.A.), Inc.
6 STREET: 4401 Hillview Ave.
7 CITY: Palo Alto
8 STATE: CA
9 COUNTRY: USA
10 ZIP: 94304

11 MEDIUM READABLE FORM:
12 MEDIUM TYPE: floppy disk
13 MEDIUM: IBM PC compatible
14 SOFTWARE: Patent Release #1.0, Version #1.25
15 CURRENT APPLICATION DATA:
16 APPLICATION NUMBER: 07 JUN 1995
17 FILING DATE: 07 JUN 1995
18 CLASSIFICATION: 435

19 ATTORNEY/AGENT INFORMATION:
20 NAME: Schmoos, William
21 REGISTRATION NUMBER: 51746
22 REFERENCE/SEQUENCE NUMBER: 076-012

23 TELEPHONE: 415-495-6593
24 TELEFAX: 415-495-6529
25 IN-EMAIL: No
26 SEQUENCE CHARACTERISTICS:
27 LENGTH: 44 amino acids
28 TYPE: amino acid
29 LOCATION: Linear

30 MEDIUM TYPE: floppy
31 HYPOTHEICAL: No
32 FRAGMENT TYPE: No
33 US-09-44-017A-2

Query Match 95.14; Score 58; DB 2; Length 44
Best Local Similarity 94.94; Gap 0.00013
Matches 11; Conservative 1; Misses 0; Gaps 0

Q7 1 AVSECTEMINUS 12
DB 1 AVSECTEMINUS 12

RESULT 12
US-09-44-017A-2
Sequence 2: Application US/044047A
Patent No. 58 7424

1 GENERAL INFORMATION:
2 APPLICANT: Kistensky, John J
3 APPLICANT: Nestor, John J
4 APPLICANT: Bo, Teresa H
5 APPLICANT: Viskery, Brian H
6 APPLICANT: Bach, Ching J

7 TITLE OF INVENTION: ANALOGS OF CARBOHYDRIDE-BINDING AND
8 TITLE OF INVENTION: PARATHYROID HORMONE-RELATED PEPTIDE: SYNTHESIS AND USE
9 NUMBER OF SEQUENCES: 86
10 CORRESPONDENCE ADDRESS:
11 ADDRESSEE: Patent Dept., Vickery (U.S.A.), Inc.
12 STREET: 4401 Hillview Ave.
13 CITY: Palo Alto
14 STATE: CA
15 COUNTRY: USA
16 ZIP: 94304

17 MEDIUM READABLE FORM:
18 MEDIUM TYPE: floppy disk
19 MEDIUM: IBM PC compatible
20 SOFTWARE: Patent Release #1.0, Version #1.25
21 CURRENT APPLICATION DATA:

ACTIVATION NUMBER: 02/04/0442

NAME: [REDACTED]

ACT. PREVALENCE: 100%

IDENTIFICATION NUMBER: 00000000000000000000

REFERENCE NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

IDENTIFICATION NUMBER: 00000000000000000000

RESULT 15
 US 07/730-174a-4
 SEARCHED 11/14/2002 08/12/2002
 INDEXED 11/14/2002 08/12/2002
 GENERAL INFORMATION
 APPLICANT: PAN, J. J.
 TITLE OF INVENTION: PARALLEL PROCESSING
 TITLE OF INVENTION: PARALLEL PROCESSING
 NUMBER OF SEQUENCES: 10
 CORRESPONDENCE ADDRESS
 ADDRESSEE: American Medical Association, Kohnstien, K.
 ADDRESS: 1725 K Street, N.W., Suite 1000
 CITY: Washington, D.C.
 COUNTRY: United States of America
 ZIP: 20006
 COMPUTER READABLE FORM
 MEDIA TYPE: Text, disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS-DOS
 SOFTWARE: Patent Release #1.2 Version #1.2
 TOP SECRET APPLICATION (TSA)
 APPLICATION NUMBER: 05/077,300
 PUBLICATION NUMBER: 05/077,300
 CLASSIFICATION: 14
 AGENCY/INSTITUTION: 14
 NAME: Muller, J. J.
 RESIDENCE NUMBER: 14
 REFERENCE NUMBER: 14
 TELEPHONE: 14
 TELEFAX: 14
 TELEFAX: 14
 TELEFAX: 14
 INFORMATION: 14
 SEQUENCE CHARACTERISTICS
 LENGTH: 14
 TYPE: AMINO ACIDS
 TOPOLOGY: 14
 MILEAGE: 14
 US 07/730-174a-4

SEARCHED 11/14/2002 08/12/2002
 INDEXED 11/14/2002 08/12/2002
 GENERAL INFORMATION

QY 1 SYSEQUENCING 14
 L4 14

Search completed: September 21, 2002, 09:41:57
 14/14/2002 08/12/2002

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

us-09-730-174a-5.open.rag

or treatment of the 120 met-oxyls dots. In addition, the present sequence would be a patent for fracture repair.

XX Best Local Similarity 100.00; Pos. 59; DB 21; Length 28;
 SQ Mismatches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

07 1 AVSEIQLMHNLG 12
 111111111111
 0b 1 avseqlmhnlg 12

RESULT 5
 AAY96015
 10 AAY96015 standard; peptide; xx aa.

XX A* AAY96015;
 XX 04-SEP-2000 (first entry)
 XX human amino-terminal modified parathyroid hormone analogue # 6.

XX parathyroid hormone peptide; 71 renal cell; osseous cell; human;
 KW signal transduction; osteoporosis; amino-terminal modification;
 KW bone disease; parathyroid hormone receptor; osteopenia;
 KW hyperparathyroidism; fracture of the hypercalcaemia; cancer; osteopathic.

XX Homo sapiens.
 OS
 PE location/2000; 1000s
 PE Modified site 1
 PE Index: "Ala 10: aspartic residue"

XX W0200001147 AL.
 XX 02-JUN-2000.
 XX 23-NOV-1999; 99NO US27656
 XX 25-NOV-1998; 98US-0110152.

XX (BRINZ) BRINCHURST F R.
 XX (TAKAZU) TAKAZU H.
 XX (GARDU) GARDU V J.

XX Brinichurst, FR, Takazu H, Gardu V J.
 XX WP: 2000-400945/44.

XX New parathyroid hormone (PTH) analogs having one or more amino acid
 substitutions that confer PTH 1-34 H 2 receptor agonist properties,
 used for treating old age osteoporosis and post-menopausal
 osteoporosis.

XX Bioscience; Page 64; 69pp; 111 44.
 XX Parathyroid hormone (PTH) bit is a PTH receptors in renal and osseous
 cells, initiating signal transduction. It has been identified that the
 carboxyl terminal of PTH is important for PTH receptor binding while the
 amino terminal is important for signal transduction. The present
 sequence is a human PTH peptide, with an amino-terminal modification
 which results in effective activation of the PTH-2 receptor and therefore
 downstream signalling. Moreover, this peptide has been implicated in a
 number of disorders: osteoporosis, osteopenia, hypoparathyroidism and
 hypercalcaemia. In turn, hypercalcaemia is associated with hypernephroma
 and a variety of cancers: breast, lung and prostate carcinoma, multiple
 myeloma and epithelial carcinoma of the head, neck and esophagus. This
 peptide would be suitable for prophylaxis and treatment of the above
 disorders. In addition, the present sequence would be suitable for
 fracture repair. The present sequence is modified to have a
 aspartic residue at position

XX Sequence: 44 AA

07 1 AVSEIQLMHNLG 12
 111111111111
 0b 1 avseqlmhnlg 12

RESULT 8
 AAY96048
 10 AAY96048 standard; peptide; xx aa.

XX A* AAY96048;
 XX 04-SEP-2000 (first entry)
 XX Human parathyroid hormone peptide; xx aa.

XX human parathyroid hormone; signal transduction; osteoporosis;
 KW osteoporosis; fracture repair; parathyroid hormone;
 KW bone disease; parathyroid hormone receptor; osteopenia;
 KW hyperparathyroidism; fracture of the hypercalcaemia; cancer; osteopathic.

XX Homo sapiens.
 OS
 PE location/2000; 1000s
 PE Modified site 1
 PE Index: "Ala 10: aspartic residue"

XX W0200001147 AL.
 XX 02-JUN-2000.
 XX 23-NOV-1999; 99NO US27656
 XX 25-NOV-1998; 98US-0110152.

XX (BRINZ) BRINCHURST F R.
 XX (TAKAZU) TAKAZU H.
 XX (GARDU) GARDU V J.

XX Brinichurst, FR, Takazu H, Gardu V J.
 XX WP: 2000-400945/44.

XX New parathyroid hormone (PTH) analogs having one or more amino acid
 substitutions that confer PTH 1-34 H 2 receptor agonist properties,
 used for treating old age osteoporosis and post-menopausal
 osteoporosis.

XX Bioscience; Page 64; 69pp; 111 44.
 XX Parathyroid hormone (PTH) bit is a PTH receptors in renal and osseous
 cells, initiating signal transduction. It has been identified that the
 carboxyl terminal of PTH is important for PTH receptor binding while the
 amino terminal is important for signal transduction. The present
 sequence is a human PTH peptide, with an amino-terminal modification
 which results in effective activation of the PTH-2 receptor and therefore
 downstream signalling. Moreover, this peptide has been implicated in a
 number of disorders: osteoporosis, osteopenia, hypoparathyroidism and
 hypercalcaemia. In turn, hypercalcaemia is associated with hypernephroma
 and a variety of cancers: breast, lung and prostate carcinoma, multiple
 myeloma and epithelial carcinoma of the head, neck and esophagus. This
 peptide would be suitable for prophylaxis and treatment of the above
 disorders. In addition, the present sequence would be suitable for
 fracture repair. The present sequence is modified to have a
 aspartic residue at position

XX Sequence: 44 AA

07 1 AVSEIQLMHNLG 12
 111111111111
 0b 1 avseqlmhnlg 12

RESULT 8
 AAY96048
 10 AAY96048 standard; peptide; xx aa.

XX A* AAY96048;
 XX 04-SEP-2000 (first entry)
 XX Human parathyroid hormone peptide; xx aa.

XX human parathyroid hormone; signal transduction; osteoporosis;
 KW osteoporosis; fracture repair; parathyroid hormone;
 KW bone disease; parathyroid hormone receptor; osteopenia;
 KW hyperparathyroidism; fracture of the hypercalcaemia; cancer; osteopathic.

XX Homo sapiens.
 OS
 PE location/2000; 1000s
 PE Modified site 1
 PE Index: "Ala 10: aspartic residue"

XX W0200001147 AL.
 XX 02-JUN-2000.
 XX 23-NOV-1999; 99NO US27656
 XX 25-NOV-1998; 98US-0110152.

XX (BRINZ) BRINCHURST F R.
 XX (TAKAZU) TAKAZU H.
 XX (GARDU) GARDU V J.

XX Brinichurst, FR, Takazu H, Gardu V J.
 XX WP: 2000-400945/44.

XX New parathyroid hormone (PTH) analogs having one or more amino acid
 substitutions that confer PTH 1-34 H 2 receptor agonist properties,
 used for treating old age osteoporosis and post-menopausal
 osteoporosis.

XX Bioscience; Page 64; 69pp; 111 44.
 XX Parathyroid hormone (PTH) bit is a PTH receptors in renal and osseous
 cells, initiating signal transduction. It has been identified that the
 carboxyl terminal of PTH is important for PTH receptor binding while the
 amino terminal is important for signal transduction. The present
 sequence is a human PTH peptide, with an amino-terminal modification
 which results in effective activation of the PTH-2 receptor and therefore
 downstream signalling. Moreover, this peptide has been implicated in a
 number of disorders: osteoporosis, osteopenia, hypoparathyroidism and
 hypercalcaemia. In turn, hypercalcaemia is associated with hypernephroma
 and a variety of cancers: breast, lung and prostate carcinoma, multiple
 myeloma and epithelial carcinoma of the head, neck and esophagus. This
 peptide would be suitable for prophylaxis and treatment of the above
 disorders. In addition, the present sequence would be suitable for
 fracture repair. The present sequence is modified to have a
 aspartic residue at position

XX Sequence: 44 AA

07 1 AVSEIQLMHNLG 12
 111111111111
 0b 1 avseqlmhnlg 12

RESULT 8
 AAY96048
 10 AAY96048 standard; peptide; xx aa.

XX A* AAY96048;
 XX 04-SEP-2000 (first entry)
 XX Human parathyroid hormone peptide; xx aa.

XX human parathyroid hormone; signal transduction; osteoporosis;
 KW osteoporosis; fracture repair; parathyroid hormone;
 KW bone disease; parathyroid hormone receptor; osteopenia;
 KW hyperparathyroidism; fracture of the hypercalcaemia; cancer; osteopathic.

XX Homo sapiens.
 OS
 PE location/2000; 1000s
 PE Modified site 1
 PE Index: "Ala 10: aspartic residue"

XX W0200001147 AL.
 XX 02-JUN-2000.
 XX 23-NOV-1999; 99NO US27656
 XX 25-NOV-1998; 98US-0110152.

QS Ratios Ratios.
 PN US496669 A.
 PD 06-NEW 1995.
 XX
 XX 21 APR 1995; 995-1341357.
 PF 21-APR 1995; 995-1341357.
 PR 09-MAY 1996; 995-1191312.
 XX
 XX (REF) MIT 6 A. 1995.
 XX
 XX Rosenblatt M. 1995-12-25.
 PF
 DR WP1; 1090-65464247.
 XX
 PF New parathyroid hormone analogs - which inhibit hormone
 PF activity by binding receptors with not producing second
 PF messenger in feedles
 XX
 PS claim 1: (claim 2: opp; failed.
 XX
 XX Peptide analogues have an activity for iih cells, as to receptors,
 XX but do not stimulate production of secondary messenger in feedles.
 XX They may be used to inhibit the iih action, and to treatles and
 XX treatment of osteoporosis, hypercalcemia and hyperparathyroidism.
 XX Analogs may also be used in treatment of tumors of iih cells
 XX (vertebral peptides) for use in treatment of tumors of iih cells
 XX est. of other inhibition and hyperactive lymphocytes.
 XX Naturally occurring iih analogs may also be measured for iih.
 XX
 SQ Sequence 44 AA.
 Query Match 100.0%; Score 59; DB 16; Length 34;
 Best Local Similarity 100.0%; Word No. 0.00045;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 95 1 AVSEIQLMHNIQ 12
 DE 1 avseiqlmhniq 12
 1.11111111
 RESULT 14
 AAR6242
 10 AAR6242 standard; peptide 1: 12 AA
 XX
 A: AAR62420;
 XX
 XX 10 APR 1997 (first entry)
 XX
 XX parathyroid hormone peptide fragment (1-44).
 XX
 KW cyclic parathyroid hormone fragment; calcium-regulating activity;
 KW osteoporosis; inhibit proliferation; epidermal cell; psoriasis;
 KW improved hair life; calcium retention; bone.
 XX
 XX Synthetic.
 XX
 XX DE:5608672-A1.
 PN
 PD 12 SEP 1996.
 XX
 XX 10-MAR 1995; 95DE-1008672
 XX
 XX 10-MAR 1995; 95DE-1008672.
 XX
 XX (REF) BIOHERINGER MANHEIM (GPH).
 XX
 XX Jany G, Esswein A, Redmann J, Renold K, Schaefer W;
 XX
 XX WP1; 1995-11551942.
 XX
 XX cyclic parathyroid hormone fragments with lactam bridge - have good
 XX in vivo hair life and are useful for treating osteoporosis and
 XX preventing epidermal cell proliferation
 XX
 XX Disclosure; Page 9; 14pp; 347 n.
 XX
 XX New cyclic parathyroid hormone fragments (CPTH) have the amino acid
 XX sequence of h, b, p, t or cth (1-84), Opt. extended by up to 4 amino
 XX acids (aa) at the C-terminus and opt. shortened by up to 3 amino acids at
 XX the N-terminus, and are cyclized between positions 13 and 17. One of
 XX these positions is occupied by t or p or n or lys, and the other by t-
 XX or D-glut or Asp. CPTH have calcium regulating activity (esp. for
 XX treating osteoporosis and inhib proliferation of epidermal cells (for
 XX treating psoriasis). The CPTH have an improved hair life in mice than
 XX known PTH fragments, increased metabolicity and DNA-synthesising
 XX capacity, reduced catabolic, calcium-mobilising activity and increased
 XX activity for calcium retention and incorporation into bone. The

DR Introduction: CROONING: Parathyroid hormone-related protein (PTHrP) is a secreted protein that is involved in the regulation of bone metabolism. It is a member of the PTH family and is produced by tumor cells. It is a secreted protein that is involved in the regulation of bone metabolism. It is a member of the PTH family and is produced by tumor cells.

Query Match: 45.49 Score: 52.1 DB: 1. Length: 119

Best Local Similarity: 75.094 Score: 100.000754 DB: 1. Length: 119

Motifs: 100 Conservative: 2 Mismatches: 1 Caps: 0

1 AVSETOFMHNLG 43

DB 12 SVSETOFMHNLG 43

RESULT 6

PTH_MWFA

1 PTH_MWFA STAN 101 115 AA

21 16-01-2002 (Ref: 14, Created)

22 16-01-2002 (Ref: 14, Last sequence update)

23 16-01-2002 (Ref: 14, Last sequence update)

24 Parathyroid hormone precursor (PTH)

25 11

26 11

27 11

28 11

29 11

30 11

31 11

32 11

33 11

34 11

35 11

36 11

37 11

38 11

39 11

40 11

41 11

42 11

43 11

44 11

45 11

46 11

47 11

48 11

49 11

50 11

DR Introduction: CROONING: Parathyroid hormone-related protein (PTHrP) is a secreted protein that is involved in the regulation of bone metabolism. It is a member of the PTH family and is produced by tumor cells. It is a secreted protein that is involved in the regulation of bone metabolism. It is a member of the PTH family and is produced by tumor cells.

Query Match: 45.49 Score: 52.1 DB: 1. Length: 119

Best Local Similarity: 75.094 Score: 100.000754 DB: 1. Length: 119

Motifs: 100 Conservative: 2 Mismatches: 1 Caps: 0

1 AVSETOFMHNLG 43

DB 12 SVSETOFMHNLG 43

RESULT 6

PTH_MWFA

1 PTH_MWFA STAN 101 115 AA

21 16-01-2002 (Ref: 14, Created)

22 16-01-2002 (Ref: 14, Last sequence update)

23 16-01-2002 (Ref: 14, Last sequence update)

24 Parathyroid hormone precursor (PTH)

25 11

26 11

27 11

28 11

29 11

30 11

31 11

32 11

33 11

34 11

35 11

36 11

37 11

38 11

39 11

40 11

41 11

42 11

43 11

44 11

45 11

46 11

47 11

48 11

49 11

50 11

Matches 3 Conservative 1 9.944 dms 13 1.33 13 0 Gaps 6

QY 1 AVSHELMING 12
3 111 11111
DB 4 SVSEELCMING 14

RESULT 7
1724
ID 1724 PRELIMINARY 194 342 AA
AC 1724
DT 1724
DI 1724
DE 1724
DN 282605
ES 1724
FA 1724
FI 1724
FL 1724
FM 1724
FN 1724
FO 1724
FR 1724
FS 1724
FT 1724
FU 1724
FV 1724
FW 1724
FX 1724
FY 1724
FZ 1724
G 1724
H 1724
I 1724
J 1724
K 1724
L 1724
M 1724
N 1724
O 1724
P 1724
Q 1724
R 1724
S 1724
T 1724
U 1724
V 1724
W 1724
X 1724
Y 1724
Z 1724
[1724
] 1724
^ 1724
_ 1724
` 1724
a 1724
b 1724
c 1724
d 1724
e 1724
f 1724
g 1724
h 1724
i 1724
j 1724
k 1724
l 1724
m 1724
n 1724
o 1724
p 1724
q 1724
r 1724
s 1724
t 1724
u 1724
v 1724
w 1724
x 1724
y 1724
z 1724
{ 1724
| 1724
} 1724
~ 1724
_ 1724
` 1724
a 1724
b 1724
c 1724
d 1724
e 1724
f 1724
g 1724
h 1724
i 1724
j 1724
k 1724
l 1724
m 1724
n 1724
o 1724
p 1724
q 1724
r 1724
s 1724
t 1724
u 1724
v 1724
w 1724
x 1724
y 1724
z 1724
{ 1724
| 1724
} 1724
~ 1724

Query Match 67.24; Score 41; DB 3; Length 586;
Best Local Similarity 58.04; Pos. 8-2;
E-value 3; Conservative 3; Matches 2; Indels 0; Gaps 0;
QY 1 AVSHELMING 12
3 111 11111
DB 4 SVSEELCMING 14

RESULT 7
1724
ID 1724 PRELIMINARY 194 342 AA
AC 1724
DT 1724
DI 1724
DE 1724
DN 282605
ES 1724
FA 1724
FI 1724
FL 1724
FM 1724
FN 1724
FO 1724
FR 1724
FS 1724
FT 1724
FU 1724
FV 1724
FW 1724
FX 1724
FY 1724
FZ 1724
G 1724
H 1724
I 1724
J 1724
K 1724
L 1724
M 1724
N 1724
O 1724
P 1724
Q 1724
R 1724
S 1724
T 1724
U 1724
V 1724
W 1724
X 1724
Y 1724
Z 1724
[1724
] 1724
^ 1724
_ 1724
` 1724
a 1724
b 1724
c 1724
d 1724
e 1724
f 1724
g 1724
h 1724
i 1724
j 1724
k 1724
l 1724
m 1724
n 1724
o 1724
p 1724
q 1724
r 1724
s 1724
t 1724
u 1724
v 1724
w 1724
x 1724
y 1724
z 1724
{ 1724
| 1724
} 1724
~ 1724

QY 1 AVSHELMING 12
3 111 11111
DB 4 SVSEELCMING 14

RESULT 7
1724
ID 1724 PRELIMINARY 194 342 AA
AC 1724
DT 1724
DI 1724
DE 1724
DN 282605
ES 1724
FA 1724
FI 1724
FL 1724
FM 1724
FN 1724
FO 1724
FR 1724
FS 1724
FT 1724
FU 1724
FV 1724
FW 1724
FX 1724
FY 1724
FZ 1724
G 1724
H 1724
I 1724
J 1724
K 1724
L 1724
M 1724
N 1724
O 1724
P 1724
Q 1724
R 1724
S 1724
T 1724
U 1724
V 1724
W 1724
X 1724
Y 1724
Z 1724
[1724
] 1724
^ 1724
_ 1724
` 1724
a 1724
b 1724
c 1724
d 1724
e 1724
f 1724
g 1724
h 1724
i 1724
j 1724
k 1724
l 1724
m 1724
n 1724
o 1724
p 1724
q 1724
r 1724
s 1724
t 1724
u 1724
v 1724
w 1724
x 1724
y 1724
z 1724
{ 1724
| 1724
} 1724
~ 1724

Query Match 67.24; Score 41; DB 3; Length 586;
Best Local Similarity 58.04; Pos. 8-2;
E-value 3; Conservative 3; Matches 2; Indels 0; Gaps 0;
QY 1 AVSHELMING 12
3 111 11111
DB 4 SVSEELCMING 14

RESULT 7
1724
ID 1724 PRELIMINARY 194 342 AA
AC 1724
DT 1724
DI 1724
DE 1724
DN 282605
ES 1724
FA 1724
FI 1724
FL 1724
FM 1724
FN 1724
FO 1724
FR 1724
FS 1724
FT 1724
FU 1724
FV 1724
FW 1724
FX 1724
FY 1724
FZ 1724
G 1724
H 1724
I 1724
J 1724
K 1724
L 1724
M 1724
N 1724
O 1724
P 1724
Q 1724
R 1724
S 1724
T 1724
U 1724
V 1724
W 1724
X 1724
Y 1724
Z 1724
[1724
] 1724
^ 1724
_ 1724
` 1724
a 1724
b 1724
c 1724
d 1724
e 1724
f 1724
g 1724
h 1724
i 1724
j 1724
k 1724
l 1724
m 1724
n 1724
o 1724
p 1724
q 1724
r 1724
s 1724
t 1724
u 1724
v 1724
w 1724
x 1724
y 1724
z 1724
{ 1724
| 1724
} 1724
~ 1724

DR PR0811F: PS002451 (HYTOCHROME-REDUCTASE)
 DR PR0811F: PS003441 (HYTOCHROME-REDUCTASE)
 FT N0811K 1
 FT N0811K 463
 SE sequence 463 AA, 5195 aa, 70622220 (PR0811F) (99%)

Query Match
 Best Local Similarity 62.5% (DB 10, Length 463)
 Matches 5, Conservative 1, Mismatches 0, Indels 0, Gaps 0

QY 5 IGFPHNGL 12
 DB 162 VYRHRSS 169
 I I I I I I I I

RESULT 13
 Q98DC3 PRELIMINARY: PR01 490 AA.
 AC Q98DC3
 DT 01-OCT-2001 (TRIMBLed, 16, Created)
 DT 01-OCT-2001 (TRIMBLed, 16, Last sequence update)
 DT 01-OCT-2001 (TRIMBLed, 16, Last annotation update)
 DE N-ACETYLGLUCOSAMINE 6-PROSEPHATE LEAFYGLASS.
 GN M014766
 CS Rhizobium loti (Neorhizobium loti)
 CC Bacteria; Proteobacteria; alpha subdivision; Rhizobiaceae group;
 CC Phyllobacteriaceae; Mesorhizobium
 CC M014766-191
 RN 11
 RP SEQUENCE FROM N.A.
 RC STRAIN MATH 322099
 RX M014766-21962999 (PubMed:1231359)
 RZ Eukaryotic, Gram-negative, aerobic, motile, nitrogen-fixing, symbiotic, and
 RA Yamada A., Ishikawa K., Kato Y., Kawashima K., Kato Y.,
 RA Eukaryotic, Gram-negative, aerobic, motile, nitrogen-fixing, symbiotic, and
 RA Kato Y., Yamada A., Ishikawa K., Kato Y., Kawashima K., Kato Y.,
 RA Kato Y., Yamada A., Ishikawa K., Kato Y., Kawashima K., Kato Y.,
 RT Complete genome sequence of the nitrogen-fixing symbiotic bacterium
 RI Neorhizobium loti
 RL LHA 802, 7,431 (3,715,330)
 DR PR0811F: PS002451 (HYTOCHROME-REDUCTASE)
 DR PR0811F: PS003441 (HYTOCHROME-REDUCTASE)
 DR InterPro: PR0004763 NacA
 DR Pfam: PF02652 NacA
 KW complete proteome
 SQ SEQUENCE FROM N.A.

Query Match
 Best Local Similarity 60.7% (DB 16, Length 463)
 Matches 5, Conservative 4, Mismatches 1, Indels 0, Gaps 0

QY 2 VAEIQMNL 11
 DB 318 IAEVRLNF 12
 I I I I I I I I

RESULT 14
 Q4993 PRELIMINARY: PR01 461 AA.
 AC Q4993
 DT 01-JUN-1998 (TRIMBLed, 06, Created)
 DT 01-JUN-1998 (TRIMBLed, 06, Last sequence update)
 DT 01-OCT-2001 (TRIMBLed, 19, Last annotation update)
 DE RNA polymerase sigma factor
 GN 5011
 CS Sinapis alba (White mustard) (Brassicaceae)
 CC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 CC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; Rosidae;
 CC Brassicaceae; Brassicaceae; Sinapis
 CC M014766-191
 RN 11
 RP SEQUENCE FROM N.A.

TISSUE-COTYLEDONS:
 RX MEDLINE 98256419; PubMed 9552134;
 RA Kostermann M., Neukirchen S., S. Spieck K., Link G.;
 R1 "Sequence and expression characteristics of a nuclear encoded
 R1 sigma factor sigma factor from mustard (Sinapis alba).";
 R1 Nucleic Acids Res. 25:2747-2754 (1996).
 CC FUNCTION: THE SIGMA FACTOR IS AN INITIATION FACTOR THAT PROMOTES
 CC ATTACHMENT OF THE RNA POLYMERASE TO SPECIFIC INITIATION SITES AND
 CC THEN IS RELEASED (BY SIMILARITY).
 CC 1 SIMILARITY: DELONGS TO THE SIGMA-70 FACTOR FAMILY.
 DE EMBL: Y15899; CAA75859.1;
 DE InterPro: IPR000943; Sigma70.
 DE Pfam: PF00140; sigma70; 1.
 DE PRINTS: PR00346; SIGMA70PCT.
 DE PROSITE: PS00715; SIGMA70.1; NFNOWN_1.
 DE RNA binding, RNA directed RNA polymerase, Sigma factor;
 KW transcription regulation.
 SQ SEQUENCE 481 AA, 54214 MW, 42547900 (PR0811F) (99%)

Query Match
 Best Local Similarity 60.7% (DB 10, Length 481)
 Matches 7, Conservative 2, Mismatches 0, Indels 0, Gaps 0

QY 1 AVSEIOPMNL 11
 DB 155 AVSEVNFQNL 165
 I I I I I I I I I I

RESULT 15
 Q9T700 PRELIMINARY: PR01 583 AA.
 AC Q9T700
 DT 01-MAY-2000 (TRIMBLed, 13, Created)
 DT 01-MAY-2000 (TRIMBLed, 13, Last sequence update)
 DT 01-MAY-2001 (TRIMBLed, 19, Last annotation update)
 DE 663 BASE (EPAGMENT).
 GN MATR
 OS Carludovicia palmata.
 CC Mitochondrion.
 CC Eukaryota; Viridiplantae; Charophyta; Embryophyta; Tracheophyta;
 CC Magnoliophyta; Magnoliophyta; Eudicotyledons; Eudicotyledons; Rosidae;
 CC Nymphaeales; Nymphaeales; Nymphaeaceae; Nymphaeaceae; Nymphaeaceae;
 RN 11
 RP SEQUENCE FROM N.A.
 RC MEDLINE 9552134; PubMed 10566879;
 RA Zanis M., Zimmer E.A., Chen E., Savolainen V., Chase M.W.;
 RT "The Earliest Angiosperms: Evidence from Mitochondrial, Plastid and
 RT Nuclear Genomes."
 RL Nature 402:404-407 (1999).
 DR EMBL: AF197734; AA114726.1;
 DR InterPro: IPR000442; Intron_mat_insd.
 DR InterPro: IPR000477; RVISE.
 DR Pfam: PF01348; Intron_maturase; 1.
 DR Pfam: PF00078; rvl; 2.
 KW Mitochondrion; RNA-directed DNA polymerase.
 FT NONTER 1
 FT NONTER 583
 SQ SEQUENCE 583 AA, 65707 MW, 121507184560ADIC (PR0811F) (99%)

Query Match
 Best Local Similarity 66.7% (DB 8, Length 583)
 Matches 6, Conservative 2, Mismatches 1, Indels 0, Gaps 0

QY 4 EIOFMHNLG 12
 DB 445 EIEFLNSG 453
 I I I I I I I I I I I I

Search completed: September 21, 2002 15:31:01

10 The present invention is a process for producing a substituted benzene derivative.
 11 In the present invention, the method of producing a substituted benzene derivative
 12 is characterized in that the substituted benzene derivative is produced by the
 13 reaction of a substituted benzene derivative with a substituted benzene derivative
 14 in the presence of a catalyst.

15 The present invention is a process for producing a substituted benzene derivative.

16 **Summary of the Invention**
 17 The present invention is a process for producing a substituted benzene derivative.
 18 The present invention is a process for producing a substituted benzene derivative.

19 **Advantages of the Invention**
 20 The present invention is a process for producing a substituted benzene derivative.

21 **Advantages of the Invention**
 22 The present invention is a process for producing a substituted benzene derivative.

23 **Advantages of the Invention**

24 **Advantages of the Invention**

25 **Advantages of the Invention**

26 **Advantages of the Invention**
 27 The present invention is a process for producing a substituted benzene derivative.

28 **Advantages of the Invention**

29 **Advantages of the Invention**

30 **Advantages of the Invention**

31 **Advantages of the Invention**

32 **Advantages of the Invention**

33 **Advantages of the Invention**

34 **Advantages of the Invention**

35 **Advantages of the Invention**

36 **Advantages of the Invention**
 37 The present invention is a process for producing a substituted benzene derivative.

38 **Advantages of the Invention**

39 **Advantages of the Invention**

40 **Advantages of the Invention**

41 **Advantages of the Invention**

42 **Advantages of the Invention**

43 **Advantages of the Invention**

44 **Advantages of the Invention**

45 **Advantages of the Invention**

46 **Advantages of the Invention**

47 **Advantages of the Invention**

48 **Advantages of the Invention**

49 **Advantages of the Invention**

50 **Advantages of the Invention**

51 **Advantages of the Invention**

52 **Advantages of the Invention**

53 **Advantages of the Invention**

54 **Advantages of the Invention**

55 **Advantages of the Invention**

56 **Advantages of the Invention**

57 **Advantages of the Invention**

58 **Advantages of the Invention**

59 **Advantages of the Invention**

60 **Advantages of the Invention**

61 **Advantages of the Invention**

62 **Advantages of the Invention**

63 **Advantages of the Invention**

64 **Advantages of the Invention**

65 **Advantages of the Invention**

66 **Advantages of the Invention**

67 **Advantages of the Invention**

68 **Advantages of the Invention**

69 **Advantages of the Invention**

70 **Advantages of the Invention**

71 **Advantages of the Invention**

72 **Advantages of the Invention**

73 **Advantages of the Invention**

74 **Advantages of the Invention**

75 **Advantages of the Invention**

76 **Advantages of the Invention**

77 **Advantages of the Invention**

78 **Advantages of the Invention**

79 **Advantages of the Invention**

80 **Advantages of the Invention**

81 **Advantages of the Invention**

82 **Advantages of the Invention**

83 **Advantages of the Invention**

84 **Advantages of the Invention**

85 **Advantages of the Invention**

86 **Advantages of the Invention**

87 **Advantages of the Invention**

88 **Advantages of the Invention**

89 **Advantages of the Invention**

90 **Advantages of the Invention**

91 **Advantages of the Invention**

92 **Advantages of the Invention**

93 **Advantages of the Invention**

94 **Advantages of the Invention**

95 **Advantages of the Invention**

SQ Sequence 1: AA

Query Match 100.0%; Score 61; DB 14; Length 41

Best Local Similarity 100.0%; Pos. No. 0.00019;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AVSEIQFMHNLG 12

Db 1 avseiqfmhnlg 12

RESULT 14

ID AAR34344 standard; peptide; 34 AA;

XX AC

XX AC

XX AC

DE 04-APR-1993 (first entry)

XX DE Bovine parathyroid hormone analogue.

XX DE bPTH mutant, substitution, osteoporosis, bone disease, calcium;

KW hypotension; smooth muscle relaxation; cardiac inotropic;

KW chromotropic; side effects; analogue.

XX OS Synthetic.

XX OS Key Location/Qual: ers

XX OS Misc-difference 23 /notes "W236 mutation"

XX PN W09306846-A.

XX PD 15-APR-1993.

XX PE 09-OCT-1992; 92WG-US08478.

XX PR 10-OCT-1991; 91US-0773097.

XX PA (PANTZ) PANG P K T.

XX PI Pang PKT, Shan J;

XX DR WPI: 1993-134128/16.

XX PI Analogues of human and bovine parathyroid hormone with

PI substitution at amino acid 23 for treating osteoporosis without

XX side effects on heart or smooth muscle

XX PS Claim 9; Fig 2b; 116pp; English

XX CC The sequence shows a bovine parathyroid hormone analogue comprising

XX a substit. at amino acid residue 23 (trp in wild type sequence). The

XX analogues are useful for treating osteoporosis and other bone diseases

XX involving calcium regulation. Unlike the natural hormone, the synthetic

XX analogues do not cause hypotension, smooth muscle relaxation or cardiac

XX inotropic or chronotropic side effects.

XX CC See also AAR34335-70.

XX SC Sequence 34 AA

Query Match 100.0%; Score 61; DB 14; Length 41

Best Local Similarity 100.0%; Pos. No. 0.00019;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AVSEIQFMHNLG 12

Db 1 avseiqfmhnlg 12

RESULT 15

Query Match 100.0%; Score 61; DB 14; Length 41

Best Local Similarity 100.0%; Pos. No. 0.00019;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AVSEIQFMHNLG 12

Db 1 avseiqfmhnlg 12

AAR34345

ID AAR34345 standard; peptide; 34 AA;

XX AC

XX AC

DE 04-APR-1993 (first entry)

XX DE Bovine parathyroid hormone analogue.

XX DE bPTH mutant, substitution, osteoporosis, bone disease, calcium;

KW hypotension; smooth muscle relaxation; cardiac inotropic;

KW chromotropic; side effects; analogue.

XX OS Synthetic.

XX OS Key Location/Qual: ers

XX OS Misc-difference 23 /notes "W236 mutation"

XX PN W09306846-A.

XX PD 15-APR-1993.

XX PE 09-OCT-1992; 92WG-US08478.

XX PR 10-OCT-1991; 91US-0773097.

XX PA (PANTZ) PANG P K T.

XX PI Pang PKT, Shan J;

XX DR WPI: 1993-134128/16.

XX PI Analogues of human and bovine parathyroid hormone with

PI substitution at amino acid 23 for treating osteoporosis without

XX side effects on heart or smooth muscle

XX PS Claim 9; Fig 2b; 116pp; English

XX CC The sequence shows a bovine parathyroid hormone analogue comprising

XX a substit. at amino acid residue 23 (trp in wild type sequence). The

XX analogues are useful for treating osteoporosis and other bone diseases

XX involving calcium regulation. Unlike the natural hormone, the synthetic

XX analogues do not cause hypotension, smooth muscle relaxation or cardiac

XX inotropic or chronotropic side effects.

XX CC See also AAR34335-70.

XX SC Sequence 34 AA;

Query Match 100.0%; Score 61; DB 14; Length 34;

Best Local Similarity 100.0%; Pos. No. 0.00019;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AVSEIQFMHNLG 12

Db 1 avseiqfmhnlg 12

Search completed, September 22, 2002, 15:21:16

Job time: 700 sec



us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

ALIGNMENTS

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

us-09-730-174a-3.closed.rsp

XX WPI: 2000-1965/22.
XX
XX Parathyroid hormone (PTH) peptides, PTH related peptides and the
PI nucleic acids that encode them, are used for treating osteoporosis -
XX
XX Disclosure: Page 26, 73pp; Figures
XX
XX The invention relates to a novel, an atthyroid hormone (PTH) peptide
XX (AA06459) and parathyroid hormone-related peptide (AA06460),
XX and biologically active derivatives thereof (AA06461-46469).
XX AA06461-46469 are peptides of the invention are at least 95%
XX identical to the active peptide of the formula:
XX X1 Val, X2 Ile, X3 Ser, X4 Asp, X5 Asn, X6 His, X7 Leu, X8 Tyr, X9
XX X1 is Ser or Ala;
XX X2 is Ile or Lys;
XX X3 is Met, Leu or Nle;
XX X4 is Asn or Asp;
XX X5 is Leu or Lys;
XX X6 is His or Ser;
XX provided that the peptide is not PTH(1-34). The peptides of the
XX invention also encompass fragments of peptide of the invention
XX consisting of amino acids 1-9, 1-10, 1-11, 1-12 and 1-13, and N- and
XX C-terminal derivatives;
XX PTH is a major regulator of calcium homeostasis, and is necessary for
XX the normal function of the gastrointestinal, skeletal, neurological
XX system, neuromuscular and cardiovascular systems. It binds to both PTH-1
XX receptors on osteoblasts and renal tubular cells, and to the recently
XX identified PTH-2 receptor. PTH has a potent anabolic effect on the
XX skeleton, and mediates calcium reabsorption, enhances phosphate
XX excretion and vitamin D synthesis in the kidney. A broad range of other
XX protein hormones, the PTH related proteins (PTHrP) mimic some of the
XX renal and skeletal actions of PTH, and also bind to the PTH-1 receptor.
XX They do not bind to the PTH-2 receptor. The peptides of the invention are
XX either agonists of PTH-1 and PTH-2 receptors (AA06461-46469), or
XX or are PTH-1/2 antagonists (AA06470-46472). AA06470-46472 are PTH-2
XX receptor antagonists are useful for the treatment of conditions
XX characterised by a decrease in bone mass, such as osteoporosis.
XX PTH-1/2 PTH-2 receptor antagonists are useful for treating medical
XX disorders that arise from excessive or altered activity of the PTH-1/2
XX receptor. Detectably labeled peptides of the invention are also useful
XX in the determination of rates of bone formation, bone resorption and/or
XX bone remodelling in a patient. The peptides of the invention are
XX "clinical seed" versions of PTH or PTHrP which are inexpensive to prepare by
XX conventional synthetic chemistry, and can be delivered to a patient via
XX non-parenteral routes. Sequences AA06461-46469 and AA06470-46472 are
XX PTH-1/2 PTH-2 receptor agonists
XX
XX Sequence: 1 AA;
XX

Query Match: 62.7%, Score: 7, DB: 21, Length: 10;
Best Local Similarity: 77.6%, Posit: 10, 6.4e-05;
Matches: 7; Conservative: 2; Mismatches: 0; Indels: 0; Caps: 0;

QY 1 SVSFTQLMH 9
DE 1 avaeqlmh 9

RESULT 13
AA064642
ID AA064642 standard; peptide, 10 AA

XX AA064642
XX AA064642 (first entry)

DE 1 avaeqlmh 9

XX Key: human; parathyroid hormone for active, calcium homeostasis;
KW hypercalcaemia, anaemia, bone disease, renal impairment, liver
KW myopathy; neuropathy, hypoparathyroidism; osteoporosis, fracture;

KW cartilage disorder; mutant; mutation;
XX
XX Bantus SP;
XX Synthetic;
XX
XX Key: Location/Qualifiers
XX
XX Mismatch: 3
XX /note: "Wild type Ser substituted by Ala"
XX
XX Mismatch: 10
XX /note: "Wild type Asn substituted by Gln"
XX
XX W2000120127-AL
XX
XX /note: "AA064642"
XX
XX 25-FEB-2000; 2000WO-0504716;
XX
XX 29-SEP-1999; 99US-0156927;
XX
XX (GENO) GEN HOSPITAL CORP.
XX
XX Cardella TJ, Krenkel RM, Smith JT, Joopner H;
XX WPI: 2001-343161/36.
XX
XX Novel amino acid encoding polypeptides useful in the treatment of
XX osteoporosis -
XX
XX Example 3; Page: 100pp; English;
XX
XX The present invention provides a number of parathyroid hormone
XX derivatives based on the rat and human hormone sequences. These peptides
XX can be used in the treatment of human skeletal conditions, including
XX osteoporosis, fractures and other bone disorders, disruption of calcium
XX homeostasis, which may cause osteoporosis, bone disease, anaemia, renal
XX impairment, hypercalcaemia, and hyperphosphatemia, hypercalcaemia and
XX hyperphosphatemia. The present peptide was used in the exemplification
XX of the invention.
XX Note: The present sequence is not shown in the specification but is
XX derived from the wild-type rat parathyroid hormone derivative shown in
XX Example 2 (see AA064696).
XX
XX Sequence: 10 AA;
XX

Query Match: 62.7%, Score: 7, DB: 21, Length: 10;
Best Local Similarity: 77.6%, Posit: 10, 1.4;
Matches: 7; Conservative: 2; Mismatches: 0; Indels: 0; Caps: 0;

QY 1 SVSFTQLMH 9
DE 1 avaeqlmh 9

RESULT 14
AA064770
ID AA064770 standard; peptide, 11 AA

XX AA064770

XX AA064770 (first entry)

DE 1 avaeqlmh 9

XX Key: Location/Qualifiers
XX
XX Modified-site: 11
XX /note: "Optional terminal amide"

XX

XX Key: Location/Qualifiers
XX
XX Modified-site: 11
XX /note: "Optional terminal amide"

Warning: Sample 174a-4.closed.rsp is not a valid sample file.

File
Name
Size
Date

Warning: Sample 174a-4.closed.rsp is not a valid sample file.

[illegible]

AA06219.
 18-SEP-2001 (first entry)
 Human parathyroid hormone immunogen c-peptide SEQ ID 1.
 Parathyroid hormone (PTH) immunoreactive peptide; human; epitope; diagnosis; calcium-metabolism disorder; osteopathy; antagonist; hypo-parathyroidism; hyperparathyroidism.
 Homo sapiens.
 181961450-A1.
 21-JUN-2001.
 17-DEC-1999; 99DE-1061450.
 17-DEC-1999; 99DE-1061450.
 (1999) HEPERSTACROSTIC AG.
 Ambrosius EP.
 2001 476318/40.
 Determining the content of physiologically active parathyroid hormone, useful in diagnosis of calcium metabolism disorders, using two antibodies reactive with different epitopes.
 Disclosure, Page 3, 10pp; German.
 This invention describes a novel method for determining (M1) the content of active parathyroid hormone (A) by treating a sample with (i) antibody (Ab1) that recognizes the epitope formed by amino acids (aa) 1-4 of (A), and including the N-terminal residue and (ii) antibody (Ab2) that recognizes an epitope within the receptor-binding site of (A). The number of molecules that react with the antibodies is determined and used to calculate the content of physiologically active (A). The method is used for diagnosis of calcium metabolism disorders, osteopathy, or hypo- or hyperparathyroidism. The method involves known assays, recognizes that (i) some fragments of (A) shorter than the complete (84 aa) peptide are active and (ii) that apparently a short peptide may be biologically inactive, and also takes into account the fact that some fragments of (A) are antagonistic (these have the receptor-binding site but lack the N-terminus). It thus provides a true measure of the content of physiologically active (A) contrast methods that measure intact peptide and its 1-47 fragment which may produce falsely high values. This sequence represents a peptide fragment used to illustrate the method of the invention.
 Sequence 10 AA
 Entry March 67,28; entry 11; DB 22; Length 9;
 Best Local Similarity 88.98; No. 5,40-05;
 Matches 6; Conservative 1; Indels 3; Gaps 0;
 2 VSSETQPMHN 10
 11111111
 1 VSSETQPMHN 9
 RESULT 5
 AAR91445
 17 AAR91445 standard; peptide 10 AA
 XX AAR91445;
 XX AAR91445;
 XX 06-IV-1996 (first entry)
 XX Human parathyroid hormone and human peptide hPTH 1-9.
 XX Human parathyroid hormone; hPTH 1-9; alpha helix; immunogen;
 XX diagnosis; active hPTH 1-9.
 XX Synthesized.
 XX 1044 84551-A1.

AA06219.
 18-SEP-2001 (first entry)
 Human parathyroid hormone immunogen c-peptide SEQ ID 1.
 Parathyroid hormone (PTH) immunoreactive peptide; human; epitope; diagnosis; calcium-metabolism disorder; osteopathy; antagonist; hypo-parathyroidism; hyperparathyroidism.
 Homo sapiens.
 181961450-A1.
 21-JUN-2001.
 17-DEC-1999; 99DE-1061450.
 17-DEC-1999; 99DE-1061450.
 (1999) HEPERSTACROSTIC AG.
 Ambrosius EP.
 2001 476318/40.
 Determining the content of physiologically active parathyroid hormone, useful in diagnosis of calcium metabolism disorders, using two antibodies reactive with different epitopes.
 Disclosure, Page 3, 10pp; German.
 This invention describes a novel method for determining (M1) the content of active parathyroid hormone (A) by treating a sample with (i) antibody (Ab1) that recognizes the epitope formed by amino acids (aa) 1-4 of (A), and including the N-terminal residue and (ii) antibody (Ab2) that recognizes an epitope within the receptor-binding site of (A). The number of molecules that react with the antibodies is determined and used to calculate the content of physiologically active (A). The method is used for diagnosis of calcium metabolism disorders, osteopathy, or hypo- or hyperparathyroidism. The method involves known assays, recognizes that (i) some fragments of (A) shorter than the complete (84 aa) peptide are active and (ii) that apparently a short peptide may be biologically inactive, and also takes into account the fact that some fragments of (A) are antagonistic (these have the receptor-binding site but lack the N-terminus). It thus provides a true measure of the content of physiologically active (A) contrast methods that measure intact peptide and its 1-47 fragment which may produce falsely high values. This sequence represents a peptide fragment used to illustrate the method of the invention.
 Sequence 9 AA
 Entry March 67,28; entry 11; DB 22; Length 9;
 Best Local Similarity 88.98; No. 5,40-05;
 Matches 6; Conservative 1; Indels 3; Gaps 0;
 2 VSSETQPMHN 10
 11111111
 1 VSSETQPMHN 9
 RESULT 5
 AAR91445
 17 AAR91445 standard; peptide 10 AA
 XX AAR91445;
 XX AAR91445;
 XX 06-IV-1996 (first entry)
 XX Human parathyroid hormone and human peptide hPTH 1-9.
 XX Human parathyroid hormone; hPTH 1-9; alpha helix; immunogen;
 XX diagnosis; active hPTH 1-9.
 XX Synthesized.
 XX 1044 84551-A1.

Copyright (c) 1994 CompuLink Ltd.

OM protein - protein search, using standard

Run on: September 21, 2002, 5:09:32, Search file: 174a-4 (without alignment)
8,613 Million cell updates/sec

Title: US-09-730-174a-4

Perfect score: 61

Sequences: 1 vs 8,160,000,000

Scoring table: BLAST/BLAST

Gapop: 1.0 / 0.05 / 1.0

Searched: 231,628 seqs, 44,255,414 residues

Total number of hits per alignment parameters: 22,222

Minimum DB seq length:

Maximum DB seq length: 1

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: 1: 5,140,000,000
2: 5,140,000,000
3: 5,140,000,000
4: 5,140,000,000
5: 5,140,000,000
6: 5,140,000,000

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	45	77.8	10	33	Sequence 1, Appl 1
2	39	63.9	9	33	Sequence 2, Appl 1
3	31	50.8	8	33	Sequence 3, Appl 1
4	29	47.5	12	33	Sequence 4, Appl 1
5	28	45.9	11	546	Sequence 5, Appl 1
6	26	42.6	7	33	Sequence 6, Appl 1
7	26	42.6	7	33	Sequence 7, Appl 1
8	25	41.0	12	33	Sequence 8, Appl 1
9	25	41.0	12	33	Sequence 9, Appl 1
10	24	39.3	5	33	Sequence 10, Appl 1
11	24	39.3	5	33	Sequence 11, Appl 1
12	24	39.3	5	33	Sequence 12, Appl 1
13	24	39.3	5	33	Sequence 13, Appl 1
14	24	39.3	5	33	Sequence 14, Appl 1
15	24	39.3	5	33	Sequence 15, Appl 1
16	24	39.3	5	33	Sequence 16, Appl 1
17	24	39.3	5	33	Sequence 17, Appl 1
18	24	39.3	5	33	Sequence 18, Appl 1
19	24	39.3	5	33	Sequence 19, Appl 1
20	24	39.3	5	33	Sequence 20, Appl 1
21	24	39.3	5	33	Sequence 21, Appl 1
22	24	39.3	5	33	Sequence 22, Appl 1
23	24	39.3	5	33	Sequence 23, Appl 1
24	24	39.3	5	33	Sequence 24, Appl 1
25	24	39.3	5	33	Sequence 25, Appl 1
26	24	39.3	5	33	Sequence 26, Appl 1
27	24	39.3	5	33	Sequence 27, Appl 1
28	24	39.3	5	33	Sequence 28, Appl 1
29	24	39.3	5	33	Sequence 29, Appl 1
30	24	39.3	5	33	Sequence 30, Appl 1
31	24	39.3	5	33	Sequence 31, Appl 1
32	24	39.3	5	33	Sequence 32, Appl 1
33	24	39.3	5	33	Sequence 33, Appl 1
34	24	39.3	5	33	Sequence 34, Appl 1
35	24	39.3	5	33	Sequence 35, Appl 1
36	24	39.3	5	33	Sequence 36, Appl 1
37	24	39.3	5	33	Sequence 37, Appl 1
38	24	39.3	5	33	Sequence 38, Appl 1
39	24	39.3	5	33	Sequence 39, Appl 1
40	24	39.3	5	33	Sequence 40, Appl 1
41	24	39.3	5	33	Sequence 41, Appl 1
42	24	39.3	5	33	Sequence 42, Appl 1
43	24	39.3	5	33	Sequence 43, Appl 1
44	24	39.3	5	33	Sequence 44, Appl 1
45	24	39.3	5	33	Sequence 45, Appl 1

Sequence 49, Appl 1
Sequence 12, Appl 1
Sequence 1, Appl 1
Sequence 83, Appl 1
Sequence 2, Appl 1
Sequence 14, Appl 1
Sequence 26, Appl 1
Sequence 2, Appl 1
Sequence 13, Appl 1
Sequence 6, Appl 1
Sequence 6, Appl 1
Sequence 9, Appl 1
Sequence 12, Appl 1
Sequence 1160, Appl 1
Sequence 7, Appl 1
Sequence 10, Appl 1
Sequence 54, Appl 1

ALIGNMENTS

RESULT 1
US-08-817-547A-1
Sequence 1, Application US/0881-547A
Patent No. 6030790
GENERAL INFORMATION:
APPLICANT: Ademann, Knut
APPLICANT: Hock, Dieter
ATTORNEY/AGENT INFORMATION:
NAME: FROST, ROGER T.
REGISTRATION NUMBER: 22,176
TELEPHONE/LOCKER NUMBER: 375.6-6507
TELECOMMUNICATION INFORMATION:
TELEPHONE: 404-818-3700
TELEFAX: 404-818-3799
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
MOLECULE TYPE: peptide
HYPOTHETICAL: no
ANTI-SENSE: no
US-08-817-547A-1

Query Match: 73.8% Score 45/ DB 3/ Length 10/
Exact local similarity: 50.0% ID: 3/ No. 0.01/
Matches: 9/ Conservative: 1/ Mismatch: 6/

REGISTRATION NUMBER: 44521
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700

Query Match 47.6% Score 29 DB 2: Length 12
 Best Local Similarity 62.0% Score 13 DB 13: Length 12
 Matches 5: Conserved 2: Mismatches 1: Incons 0: Gaps 0:

QY 2 SVSEIQPM 9
 DB 1 SVSEIQPM 12

RESULT 5
 US-09-730-174A-4

Patent No. 546078
 APPLICANT: MARTIN, JEROME L.
 TITLE OF INVENTION: A METHOD FOR THE
 IDENTIFICATION OF Amino Acids
 NUMBER OF SEQUENCES: 4
 CURRENT APPLICATION DATA:
 FILING DATE: 11-01-1991
 FILING DATE: 11-01-1991
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700

Query Match 45.94% Score 28 DB 6: Length 12
 Best Local Similarity 60.00% Score 19 DB 19: Length 12
 Matches 6: Conserved 1: Mismatches 5: Incons 0: Gaps 0:

QY 1 SVSEIQPM 10
 DB 1 SVSEIQPM 10

RESULT 6
 US-09-730-174A-4

Patent No. 546078
 APPLICANT: MARTIN, JEROME L.
 TITLE OF INVENTION: A METHOD FOR THE
 IDENTIFICATION OF Amino Acids
 NUMBER OF SEQUENCES: 4
 CURRENT APPLICATION DATA:
 FILING DATE: 11-01-1991
 FILING DATE: 11-01-1991
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700

REGISTRATION NUMBER: 44521
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700

Query Match 42.6% Score 26 DB 3: Length 6
 Best Local Similarity 100.00% Score 2: Length 6
 Matches 6: Conserved 0: Mismatches 0: Incons 0: Gaps 0:

QY 1 SVSEIQ 6
 DB 1 SVSEIQ 6

RESULT 7

US-09-730-174A-4
 Patent No. 546078
 APPLICANT: Adermann, Knut
 TITLE OF INVENTION: Peptides from the hPTH Sequence
 NUMBER OF SEQUENCES: 36
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700
 CURRENT APPLICATION DATA:
 FILING DATE: 29 SEPT 1994
 FILING DATE: 29 SEPT 1994
 NAME: FROST, ROGER T.
 REGISTRATION NUMBER: 22,17
 REFERENCE/SEQUENCE NUMBER: 100.00%
 TELEPHONE: 404-818-3700
 TELEFAX: 404-818-3700


```

1  ZIP: 30309-416
2  COMPUTER RELEASABLE FORM:
3  MEDIUM TYPE: Floppy disk
4  COMPUTER: IBM PC compatible
5  OPERATING SYSTEM: PC DOS/MS-DOS
6  SOFTWARE: Patent Release #1.0 Version #1.25
7  CURRENT APPLICATION NUMBER: 09/09/2002 09A
8  FILING DATE: 29 SEPT 1994
9  CLASSIFICATION: 11
10  ATTORNEY/AGENT INFORMATION:
11  NAME: FROST, ROGER L.
12  REGISTRATION NUMBER: 11281
13  REFERENCE/DRAWING NUMBER: WP 174-117
14  INFORMATION FOR SEQUENCE:
15  LENGTH: 5 amino acids
16  TYPE: amino acid
17  MOLECULE TYPE: peptide
18  HYDROPHILIC: no
19  STRANDNESS: unknown
20  SEQUENCE CHARACTERISTICS:
21  LENGTH: 5 amino acids
22  TYPE: amino acid
23  MOLECULE TYPE: peptide
24  HYDROPHILIC: no
25  STRANDNESS: unknown
26  INFORMATION FOR SEQUENCE:
27  LENGTH: 5 amino acids
28  TYPE: amino acid
29  MOLECULE TYPE: peptide
30  HYDROPHILIC: no
31  STRANDNESS: unknown
32  US-09-730-174a-4

```

```

Query Match: 39.9% Seq-24, 100% Seq-25, Length 5:
Best Local Similarity: 60.00% Seq-1, No. 1.7e+05;
Matches: 3; Conservative: 0; Mismatches: 0; Gaps: 0;

```

```

Q7 8 MINIG 12
11
16 1 LENMG 5

```

```

RESULT 11
US-09-667-56-56
1 Sequence: 56, Application: 1 US/09/09/2002
2 Patent No: 5928692
3 GENERAL INFORMATION:
4 APPLICANT: Jackson, Ronald L.
5 TITLE OF INVENTION: METHOD FOR IDENTIFYING PEPTIDES
6 NUMBER OF SEQUENCES: 62
7 CORRESPONDENCE ADDRESS:
8 ADDRESSEE: Jackson, Ronald L.
9 STREET: 2400 N. Peachtree Street, N.E.
10 CITY: Atlanta, GA
11 STATE: Georgia
12 COUNTRY: USA
13 ZIP: 30309-416
14 COMPUTER RELEASABLE FORM:
15 MEDIUM TYPE: Floppy disk
16 COMPUTER: IBM PC compatible
17 OPERATING SYSTEM: PC DOS/MS-DOS
18 SOFTWARE: Patent Release #1.0 Version #1.25
19 CURRENT APPLICATION NUMBER: 09/09/2002 09A
20 FILING DATE: 29 SEPT 1994
21 CLASSIFICATION: 11
22 ATTORNEY/AGENT INFORMATION:
23 NAME: FROST, ROGER L.
24 REGISTRATION NUMBER: 11281
25 REFERENCE/DRAWING NUMBER: WP 174-117
26 INFORMATION FOR SEQUENCE:
27 LENGTH: 5 amino acids
28 TYPE: amino acid
29 MOLECULE TYPE: peptide
30 HYDROPHILIC: no
31 STRANDNESS: unknown
32 US-09-667-56-56

```

```

1 SEQUENCE CHARACTERISTICS:
2 LENGTH: 5 amino acids
3 TYPE: amino acid
4 MOLECULE TYPE: linear
5 HYDROPHILIC: no
6 STRANDNESS: unknown
7 INFORMATION FOR SEQUENCE:
8 LENGTH: 5 amino acids
9 TYPE: amino acid
10 MOLECULE TYPE: peptide
11 HYDROPHILIC: no
12 STRANDNESS: unknown
13 US-09-667-56-56

```

```

Query Match: 39.9% Seq-24, 100% Seq-25, Length 5:
Best Local Similarity: 60.00% Seq-1, No. 1.7e+05;
Matches: 3; Conservative: 0; Mismatches: 0; Gaps: 0;

```

```

Q7 8 MINIG 12
11
16 1 LENMG 5

```

```

RESULT 12
US-09-817-547A-17
1 Sequence: 17, Application: US/09/09/2002 17A
2 Patent No: 6040790
3 GENERAL INFORMATION:
4 APPLICANT: Ademann, Knut
5 TITLE OF INVENTION: Peptides from the hPTH Sequence
6 NUMBER OF SEQUENCES: 36
7 CORRESPONDENCE ADDRESS:
8 ADDRESSEE: Jones & Askew, Inc.
9 STREET: 191 Peachtree Street, 3rd Floor
10 CITY: Atlanta, GA
11 STATE: Georgia
12 COUNTRY: USA
13 ZIP: 30304
14 COMPUTER RELEASABLE FORM:
15 MEDIUM TYPE: Floppy disk
16 COMPUTER: IBM PC compatible
17 OPERATING SYSTEM: PC DOS/MS-DOS
18 SOFTWARE: Patent Release #1.0, Version #1.30
19 CURRENT APPLICATION DATA:
20 APPLICATION NUMBER: 09/09/2002 17A
21 FILING DATE:
22 PRIOR APPLICATION DATA:
23 APPLICATION NUMBER: 09/09/2002 17
24 FILING DATE: 29 SEPT 1994
25 ATTORNEY/AGENT INFORMATION:
26 NAME: FROST, ROGER L.
27 REGISTRATION NUMBER: 11281
28 REFERENCE/DRAWING NUMBER: WP 174-117
29 INFORMATION FOR SEQUENCE:
30 LENGTH: 5 amino acids
31 TYPE: amino acid
32 MOLECULE TYPE: peptide
33 HYDROPHILIC: no
34 STRANDNESS: unknown
35 US-09-817-547A-17

```

```

Query Match: 39.9% Seq-24, 100% Seq-25, Length 5:
Best Local Similarity: 100.00% Seq-1, No. 1.7e+05;
Matches: 4; Conservative: 0; Mismatches: 0; Gaps: 0;

```

```

Q7 9 MINIG 12
11
16 1 LENMG 4

```



```

: INFORMATION FOR SEQ 1: NO: 64.
: SEQUENCE CHARACTERISTICS:
:   LENGTH: 8 amino acids
:   TYPE: amino acid
:   STRANDNESS: 8 bitle
:   TAG: none
:   FEATURE:
:     NAME/KEY: Modified site
:     LOCATION: 1
:     OTHER INFORMATION: /label="OTHER"
:     OTHER INFORMATION: /label="His"
:     OTHER INFORMATION: /label="Serine"
US-08-748-021-64

```

```

Query Match: 39.4% Score: 24; DB: 2; Length: 8;
Best Local Similarity: 100.0%; Prev. No: 1.7e+05;
Matches: 4; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;

```

```


CY 9 BNG 12
16 2 BNG 5

```

```

Search completed: September 21, 2002, 13:04:32
Job time: 131 sec

```



GenCore version 4.5
Copyright (c) 1993-1999 Compaq Inc.

QM protein - protein alignment results

Run on: Sept 16 2002 16:07:16 Search time 14.67 seconds
(without alignments)
26,696 Million cell updates/sec

Title: US-09-730-174a-5

Perfect score: 59

Sequence: 1 AVSFLIMNIG 12

Scoring table: dms 2%

Gapop 1.0, Gapext 5.0

Searched: 283100 seqs, 960000 residues

Total number of hits satisfying chosen parameters: 137

Minimum DB seq length: 9

Maximum DB seq length: 1

Best alignment: Minimum Match %

Maximum Match %

Listing first 45 summaries

Database:

- 1: p1r711*
- 2: p1r21*
- 3: p1r1*
- 4: p1r4*

Pred. No. is the number of residues predicted by choice to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

COMPACTS

Result No.	Score	Match	Length	DB	Description
1	21	65.6	12	2	1: heavy chain V r
2	18	40.5	9	2	carcinein 0144 - Ca
3	18	40.5	9	2	ribosomal protein
4	18	40.5	10	2	sperm activating p
5	18	40.5	10	2	and isen p20e pre
6	18	40.5	12	2	6-aminimidazole r
7	17	28.8	7	2	oligomycin heavy
8	17	28.8	10	2	13 heavy chain V r
9	17	28.8	12	2	cell receptor al
10	17	28.8	12	2	cell receptor al
11	17	28.8	12	2	cell receptor al
12	16	27.1	10	2	placental lactose
13	16	27.1	11	2	cell receptor be
14	15	25.4	7	2	p1r711
15	15	25.4	7	2	polyphosphatase
16	15	25.4	9	2	chlorophyll a/b bi
17	15	25.4	9	2	N-methylpurine DNA
18	15	25.4	19	2	cell receptor qa
19	15	25.4	11	2	lecithin hemolys
20	15	25.4	11	2	translational elonga
21	15	25.4	11	2	transprotein beta
22	14	24.7	4	2	cell receptor al
23	14	24.7	7	2	RNA dehydrogenase
24	14	24.7	9	2	heavy chain CRD
25	14	24.7	10	2	transmembrane K2 p1r
26	14	24.7	10	2	transmembrane K2 p1r
27	14	24.7	10	2	transmembrane K2 p1r
28	14	24.7	10	2	transmembrane K2 p1r
29	14	24.7	10	2	transmembrane K2 p1r
30	14	24.7	10	2	transmembrane K2 p1r

30 14 23.7 11 2 S03454
31 14 23.7 11 2 H23856
32 14 23.7 11 2 541009
33 14 23.7 12 2 820485
34 14 23.7 12 2 140410
35 14 23.7 12 2 141015
36 14 23.7 12 2 551014
37 14 23.7 12 2 551014
38 14 23.7 12 2 551014
39 14 23.7 12 2 551014
40 14 23.7 12 2 551014
41 14 23.7 12 2 551014
42 14 23.7 12 2 551014
43 14 23.7 12 2 551014
44 14 23.7 12 2 551014
45 14 23.7 12 2 551014

ALIGNMENTS

RESULT 1

S21205

14 heavy chain V region - human

C:Species: Homo sapiens (man)

C:Accession: S21205

C:Residues: 1-12

C:Keywords: heterodimer; immunoglobulin

C:Title: Placental alkaline phosphatase has a binding site for the human immunoglobulin

C:Abstract: Placental alkaline phosphatase has a binding site for the human immunoglobulin

C:Accession: S21205

C:Status: preliminary

C:Molecule type: protein

C:Residues: 1-12

C:Keywords: heterodimer; immunoglobulin

Query Match 25.6%

Best Local Similarity 44.4%

Mismatches 4

Conservative 1

Indels 0

Gaps 0

RESULT 2

A58718

carcinein 0144 - Carnobacterium sp. (raiment)

C:Species: Carnobacterium sp.

C:Accession: A58718

C:Residues: 1-7

C:Keywords: antibiotic; lanthionine

C:Title: Purification and characterization of a new bacteriocin isolated from a Carno

C:Abstract: Purification and characterization of a new bacteriocin isolated from a Carno

C:Accession: A58718

C:Status: preliminary

C:Molecule type: protein

C:Residues: 1-7

C:Keywords: antibiotic; lanthionine

Query Match 30.6%

Best Local Similarity 100.0%

Mismatches 4

Conservative 1

Indels 0

Gaps 0

SEIO 6

SEIO 5

Accession: F12-07AS

Query Match 28.8%; Score 27; DB 2; Length 12;
 Best Local Similarity 44.4%; Ident. No. 4; Gaps 0;
 Matches 4; Conservative 1; Mismatches 0;

QY 1 AVSR 4
 1 1 1 1
 DB 1 ESQSEFNAV 9

RESULT 9

PHIL9
 T cell receptor alpha chain V region (V8/10/1) human (fragment)
 Species: Homo sapiens (hum)
 Date: 16-Jul-1999 #sequence 16-Jul-1999 #ext_change 16-Jul-1999
 Accession: PHIL9
 Release: 16-Jul-1999
 J. Exp. Med. 176: 439-447, 1992
 A. Title: B-2 receptor of lymphocytes specific for B-2 display T cell receptor
 A. Ref: 16-Jul-1999 #sequence 16-Jul-1999 #ext_change 16-Jul-1999
 A. Accession: PHIL9
 A. Status: Preliminary
 A. Molecule type: mRNA
 A. Accession: F12-07AS

Query Match 29.9%; Score 17; DB 2; Length 10;
 Best Local Similarity 100.0%; Ident. No. 4; Gaps 0;
 Matches 4; Conservative 1; Mismatches 0;

QY 1 AVSR 4
 1 1 1 1
 DB 2 AVSR 5

RESULT 10

PHIL9
 T cell receptor alpha chain V region (V8/10/1) human (fragment)
 Species: Homo sapiens (hum)
 Date: 16-Jul-1999 #sequence 16-Jul-1999 #ext_change 16-Jul-1999
 Accession: PHIL9
 Release: 16-Jul-1999
 J. Exp. Med. 176: 439-447, 1992
 A. Title: B-2 receptor of lymphocytes specific for B-2 display T cell receptor
 A. Ref: 16-Jul-1999 #sequence 16-Jul-1999 #ext_change 16-Jul-1999
 A. Accession: PHIL9
 A. Status: Preliminary
 A. Molecule type: mRNA
 A. Accession: F12-07AS

Query Match 28.8%; Score 27; DB 2; Length 12;
 Best Local Similarity 44.4%; Ident. No. 4; Gaps 0;
 Matches 4; Conservative 1; Mismatches 0;

QY 1 AVSR 4
 1 1 1 1
 DB 2 AVSR 5

RESULT 11

PHIL9
 T cell receptor alpha chain V region (V8/10/1) human (fragment)
 Species: Homo sapiens (hum)
 Date: 16-Jul-1999 #sequence 16-Jul-1999 #ext_change 16-Jul-1999
 Accession: PHIL9
 Release: 16-Jul-1999
 J. Exp. Med. 176: 439-447, 1992
 A. Title: B-2 receptor of lymphocytes specific for B-2 display T cell receptor
 A. Ref: 16-Jul-1999 #sequence 16-Jul-1999 #ext_change 16-Jul-1999
 A. Accession: PHIL9

Accession: Preliminary
 Molecule type: mRNA
 Accession: F12-07AS

Query Match 28.8%; Score 27; DB 2; Length 12;
 Best Local Similarity 100.0%; Ident. No. 4; Gaps 0;
 Matches 4; Conservative 1; Mismatches 0;

QY 1 AVSR 4
 1 1 1 1
 DB 2 AVSR 5

RESULT 12

PHIL9
 T cell receptor alpha chain V region (V8/10/1) human (fragment)
 Species: Mus sp. (mouse)
 Date: 12-Apr-1996 #sequence 12-Apr-1996 #ext_change 12-Apr-1996
 Accession: A47464
 Release: 12-Apr-1996
 J. Biol. Chem. 271: 181-188, 1994
 A. Title: T cell receptor specific for B-2 display T cell receptor
 A. Ref: 12-Apr-1996 #sequence 12-Apr-1996 #ext_change 12-Apr-1996
 A. Accession: A47464
 A. Status: Preliminary, translated from GB/EMBL/DBJ
 A. Molecule type: DNA
 A. Accession: F12-07AS
 A. Accession: F12-07AS

Query Match 27.1%; Score 16; DB 2; Length 10;
 Best Local Similarity 57.1%; Ident. No. 5; Gaps 0;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 5 GEMINI 11
 1 1 1 1
 DB 1 MQLINI 7

RESULT 13

PHIL9
 T cell receptor beta chain V-D-J region (isolate 10) - rat (fragment)
 Species: Rattus norvegicus (Norway rat)
 Date: 12-Apr-1992 #sequence 12-Apr-1992 #ext_change 12-Apr-1992
 Accession: PHIL9
 Release: 12-Apr-1992
 J. Biol. Chem. 267: 1467-1476, 1991
 A. Title: Analysis of T cell receptor beta chains in Lewis rats with experimental alle
 A. Ref: 12-Apr-1992 #sequence 12-Apr-1992 #ext_change 12-Apr-1992
 A. Accession: PHIL9
 A. Status: Preliminary
 A. Molecule type: mRNA
 A. Accession: F12-07AS
 A. Accession: F12-07AS

Query Match 27.1%; Score 16; DB 2; Length 11;
 Best Local Similarity 50.0%; Ident. No. 5; Gaps 0;
 Matches 4; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 AVSR10M 8
 1 1 1 1
 DB 2 AVSR10M 9

RESULT 14

PHIL9
 T cell receptor beta chain V-D-J region (isolate 10) - rat (fragment)
 Species: Rattus norvegicus (Norway rat)
 Date: 12-Apr-1992 #sequence 12-Apr-1992 #ext_change 12-Apr-1992
 Accession: PHIL9
 Release: 12-Apr-1992
 J. Biol. Chem. 267: 1467-1476, 1991
 A. Title: Analysis of T cell receptor beta chains in Lewis rats with experimental alle
 A. Ref: 12-Apr-1992 #sequence 12-Apr-1992 #ext_change 12-Apr-1992
 A. Accession: PHIL9





1. The first step is to identify the problem. This involves understanding the current situation and what needs to be changed.

2. The second step is to set goals. These should be specific, measurable, achievable, relevant, and time-bound (SMART).

3. The third step is to develop a plan. This involves determining the steps that need to be taken to achieve the goals.

4. The fourth step is to implement the plan. This involves putting the plan into action and monitoring progress.

5. The fifth step is to evaluate the results. This involves assessing whether the goals have been achieved and what lessons can be learned.

1. $\frac{1}{2}$
 2. $\frac{1}{2}$
 3. $\frac{1}{2}$
 4. $\frac{1}{2}$
 5. $\frac{1}{2}$
 6. $\frac{1}{2}$
 7. $\frac{1}{2}$
 8. $\frac{1}{2}$
 9. $\frac{1}{2}$
 10. $\frac{1}{2}$
 11. $\frac{1}{2}$
 12. $\frac{1}{2}$
 13. $\frac{1}{2}$
 14. $\frac{1}{2}$
 15. $\frac{1}{2}$
 16. $\frac{1}{2}$
 17. $\frac{1}{2}$
 18. $\frac{1}{2}$
 19. $\frac{1}{2}$
 20. $\frac{1}{2}$
 21. $\frac{1}{2}$
 22. $\frac{1}{2}$
 23. $\frac{1}{2}$
 24. $\frac{1}{2}$
 25. $\frac{1}{2}$
 26. $\frac{1}{2}$
 27. $\frac{1}{2}$
 28. $\frac{1}{2}$
 29. $\frac{1}{2}$
 30. $\frac{1}{2}$
 31. $\frac{1}{2}$
 32. $\frac{1}{2}$
 33. $\frac{1}{2}$
 34. $\frac{1}{2}$
 35. $\frac{1}{2}$
 36. $\frac{1}{2}$
 37. $\frac{1}{2}$
 38. $\frac{1}{2}$
 39. $\frac{1}{2}$
 40. $\frac{1}{2}$
 41. $\frac{1}{2}$
 42. $\frac{1}{2}$
 43. $\frac{1}{2}$
 44. $\frac{1}{2}$
 45. $\frac{1}{2}$
 46. $\frac{1}{2}$
 47. $\frac{1}{2}$
 48. $\frac{1}{2}$
 49. $\frac{1}{2}$
 50. $\frac{1}{2}$
 51. $\frac{1}{2}$
 52. $\frac{1}{2}$
 53. $\frac{1}{2}$
 54. $\frac{1}{2}$
 55. $\frac{1}{2}$
 56. $\frac{1}{2}$
 57. $\frac{1}{2}$
 58. $\frac{1}{2}$
 59. $\frac{1}{2}$
 60. $\frac{1}{2}$
 61. $\frac{1}{2}$
 62. $\frac{1}{2}$
 63. $\frac{1}{2}$
 64. $\frac{1}{2}$
 65. $\frac{1}{2}$
 66. $\frac{1}{2}$
 67. $\frac{1}{2}$
 68. $\frac{1}{2}$
 69. $\frac{1}{2}$
 70. $\frac{1}{2}$
 71. $\frac{1}{2}$
 72. $\frac{1}{2}$
 73. $\frac{1}{2}$
 74. $\frac{1}{2}$
 75. $\frac{1}{2}$
 76. $\frac{1}{2}$
 77. $\frac{1}{2}$
 78. $\frac{1}{2}$
 79. $\frac{1}{2}$
 80. $\frac{1}{2}$
 81. $\frac{1}{2}$
 82. $\frac{1}{2}$
 83. $\frac{1}{2}$
 84. $\frac{1}{2}$
 85. $\frac{1}{2}$
 86. $\frac{1}{2}$
 87. $\frac{1}{2}$
 88. $\frac{1}{2}$
 89. $\frac{1}{2}$
 90. $\frac{1}{2}$
 91. $\frac{1}{2}$
 92. $\frac{1}{2}$
 93. $\frac{1}{2}$
 94. $\frac{1}{2}$
 95. $\frac{1}{2}$
 96. $\frac{1}{2}$
 97. $\frac{1}{2}$
 98. $\frac{1}{2}$
 99. $\frac{1}{2}$
 100. $\frac{1}{2}$

[illegible]

The figure is a flowchart illustrating the experimental design. It is organized into two main vertical columns: 'Pre-Test' and 'Test'.
 In the 'Pre-Test' column:
 - 'Pre-Test 1' is at the top, with 'Pre-Test 1a' and 'Pre-Test 1b' branching off to the right.
 - Below 'Pre-Test 1' is 'Pre-Test 2'.
 In the 'Test' column:
 - 'Test 1' is at the top, with 'Test 1a' and 'Test 1b' branching off to the right.
 - Below 'Test 1' is 'Test 2'.
 At the bottom of the 'Test' column is a box labeled 'Result'.
 Arrows indicate the flow from 'Pre-Test 1' to 'Pre-Test 2' and from 'Test 1' to 'Test 2'. There are also arrows pointing from 'Pre-Test 1a' and 'Pre-Test 1b' to 'Pre-Test 2', and from 'Test 1a' and 'Test 1b' to 'Test 2'. A final arrow points from 'Test 2' to the 'Result' box.

$\frac{1}{2} \log \frac{1}{2}$

$$\mathcal{L}_i^*(\mathbf{r}) = \mathbf{r} \cdot \mathbf{k} + c; \quad \mathbf{r} \in \mathbb{R}^2, \mathbf{k} \in \mathbb{M}_1.$$
[illegible][illegible][illegible]
$$A_{\infty}(\tilde{u}, \tilde{v}, \tilde{w}) = \lim_{n \rightarrow \infty} A_n(\tilde{u}, \tilde{v}, \tilde{w})$$

2000		2001		2002		2003		2004		2005		2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016		2017		2018		2019		2020		2021		2022		2023		2024		2025		2026		2027		2028		2029		2030		2031		2032		2033		2034		2035		2036		2037		2038		2039		2040		2041		2042		2043		2044		2045		2046		2047		2048		2049		2050		2051		2052		2053		2054		2055		2056		2057		2058		2059		2060		2061		2062		2063		2064		2065		2066		2067		2068		2069		2070		2071		2072		2073		2074		2075		2076		2077		2078		2079		2080		2081		2082		2083		2084		2085		2086		2087		2088		2089		2090		2091		2092		2093		2094		2095		2096		2097		2098		2099		2100	
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100																																																																																																						

Age Group	Male	Female
0-14	10	5
15-24	85	40
25-34	45	25
35-44	35	20
45-54	25	15
55-64	15	10
65-74	10	5
75-84	5	2
85+	2	1

The diagram illustrates the experimental setup. A participant is seated at a table, looking at a monitor. On the table is a 3D model of a human head and neck. A red line on the model indicates the larynx. The participant is instructed to perform a task, and the setup is designed to measure the laryngeal position and movement during speech production. The diagram includes labels for the participant, the monitor, the 3D model, and the larynx.

Figure 1 displays a 4x4 grid of 16 small images, likely representing different stages of a bird's development or life cycle. The images are arranged in four rows and four columns. The first row shows a single egg. The second row shows a small, downy chick. The third row shows a slightly larger, more developed chick. The fourth row shows a fully formed adult bird. The images are arranged in a grid that is 4 rows by 4 columns.

[illegible]

Trial	Control (n=10)	MCI (n=10)	AD (n=10)
1	95	85	75
2	95	85	75
3	95	80	70
4	95	75	65
5	95	75	65

[illegible]

1. \mathcal{H} is a Hilbert space.
 2. \mathcal{H} is a Banach space.
 3. \mathcal{H} is a normed space.
 4. \mathcal{H} is a metric space.
 5. \mathcal{H} is a topological space.
 6. \mathcal{H} is a vector space.
 7. \mathcal{H} is a linear space.
 8. \mathcal{H} is a normed linear space.
 9. \mathcal{H} is a Banach space.
 10. \mathcal{H} is a Hilbert space.

[illegible][illegible]

Downloaded from ascelibrary.org by University of California, San Diego on 06/01/15. Copyright ASCE, For All Rights Reserved, No part of this document may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without permission in writing from ASCE.


```

US-08-817-547A-4
RESULT 5
Sequence 4, Application 08/08/95/1717
Patent No. 695696
GENERAL INFORMATION:
APPLICANT: IBM Corp., FI
INVENTOR: John J. F.
APPLICANT: Marking Marks
TITLE OF INVENTION: Peptides from the HPH Sequence
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Janssen Asken, LLC
STREET: 191 Peachtree Street, 17th Floor
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/08/95/1717
FILING DATE: 08/08/95
CLASSIFICATION: 514
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-428-257A-14
Query Match 42.8% (Score 25, EP 2; Length 10;
Best Local Similarity 83.3% (ID 1, No. 81;
Matches 5; Conservative 1; Identical 0; Gaps 0;
QV 2 VSSEQ 7
DB 1 VSSEQ 6
RESULT 7
US-08-802-981-124
Sequence 124, Application 08/03/98/151
Patent No. 6037137
GENERAL INFORMATION:
APPLICANT: Kemerly, Alira
INVENTOR: Packard, Beverly S
TITLE OF INVENTION: Composit GAs for the Detection of Enzyme
APPLICATION NUMBER: 08/03/98/151
FILING DATE: 03/03/98
CLASSIFICATION: 231
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/03/98/151
FILING DATE: 20-FEB-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Hunter, Tom
REGISTRATION NUMBER: 38,494
REFERENCE/DOCKET NUMBER: 61065 00030005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 154:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
NAME/FEY: Modified-site
LOCATION: 3
OTHER INFORMATION: /product: "Ald"
US-08-802-981-124
US-08-817-547A-4
Sequence 4, Application 08/08/95/1717
Patent No. 695696
GENERAL INFORMATION:
APPLICANT: IBM Corp., FI
INVENTOR: John J. F.
APPLICANT: Marking Marks
TITLE OF INVENTION: Peptides from the HPH Sequence
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Janssen Asken, LLC
STREET: 191 Peachtree Street, 17th Floor
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/08/95/1717
FILING DATE: 08/08/95
CLASSIFICATION: 514
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-428-257A-14
Query Match 45.8% (Score 27; DB 3; Length 7
Best Local Similarity 85.7% (ID 3; No. 172-95;
Matches 6; Conservative 1; Identical 0; Gaps 0;
QV 1 VSSEQ 7
DB 1 VSSEQ 7
RESULT 5
US-08-428-257A-14
Sequence 4, Application 08/08/95/1717
Patent No. 695696
GENERAL INFORMATION:
APPLICANT: Spencet, Robert A.
INVENTOR: Epenet, A. A.
TITLE OF INVENTION: Grafts for Target Cells
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Janssen Asken, LLC
STREET: 191 Peachtree Street, 17th Floor
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/08/95/1717
FILING DATE: 08/08/95
CLASSIFICATION: 514
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
NAME/FEY: Modified-site
LOCATION: 3
OTHER INFORMATION: /product: "Ald"
US-08-802-981-124

```


NAME: FRANK, ROBERT
 REGISTRATION NUMBER: 220174
 REFERENCE/DOCKET NUMBER: 01/05/95
 TELECOMMUNICATION INFORMATION
 TELEPHONE: 404-817-5474
 TELEFAX: 404-817-3799
 IN-SEMI-AN FOR SEQ. IN NO. 174
 SEQUENCE CHARACTERISTICS
 LENGTH: 5 amino acids
 TYPE: amino acid
 STRANDEDNESS: unknown
 T 3rd. way: unknown
 MOLECULE TYPE: peptide
 ANTI-SENSE: no
 US-08-817-547A-17

Query Match 40.7% Seq. ID: 34, DB 3, Length 6;
 Best Local Similarity 100.0% Pat. No. 1,76+05;
 Mismatches 0; Indels 0; Caps 0;
 07 9 HNS 12
 14 1 HNS 4

RESULT 11
 US-08-817-547A-16
 : Sequence 16, Application US/08/017547A
 : Patent No. 6031796
 : GENERAL INFORMATION:
 : APPLICANT: Admarr, Knut
 : APPLICANT: Admarr, Knut
 : APPLICANT: Admarr, Knut
 : TITLE OF INVENTION: Peptides in the hPTH Sequence
 : NUMBER OF SEQUENCES: 36
 : CORRESPONDENCE ADDRESS:
 : ADDRESS: Jones & Askew, LLC
 : STREET: 191 Peachtree Street, 17th Floor
 : CITY: Atlanta
 : STATE: Georgia
 : ZIP: 30303
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: floppy disk
 : OPERATING SYSTEM: IBM PC compatible
 : SOFTWARE: Patent In Release #1.0, Version #1.0
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/08/017547A
 : FILING DATE:
 : PRIOR APPLICATION DATA:
 : APPLICATION NUMBER: PCT/US-95/03757
 : FILING DATE: 29 SEPT 1994
 : ATTORNEY/AGENT INFORMATION:
 : NAME: FRANK, ROBERT
 : REGISTRATION NUMBER: 22,174
 : REFERENCE/DOCKET NUMBER: 01/05/95
 : TELECOMMUNICATION INFORMATION:
 : TELEPHONE: 404-817-3799
 : TELEFAX: 404-817-3799
 : IN-SEMI-AN FOR SEQ. IN NO. 174
 : SEQUENCE CHARACTERISTICS:
 : LENGTH: 5 amino acids
 : TYPE: amino acid
 : STRANDEDNESS: unknown
 : MOLECULE TYPE: peptide
 : ANTI-SENSE: no
 : US-08-817-547A-17

Query Match 40.7% Seq. ID: 34, DB 3, Length 6;
 Best Local Similarity 100.0% Pat. No. 1,76+05;
 Mismatches 0; Indels 0; Caps 0;
 07 9 HNS 12
 14 1 HNS 4

RESULT 12
 US-08-817-547A-15
 : Sequence 15, Application US/08/017547A
 : Patent No. 6031790
 : GENERAL INFORMATION:
 : APPLICANT: Admarr, Knut
 : APPLICANT: Admarr, Knut
 : APPLICANT: Admarr, Knut
 : TITLE OF INVENTION: Peptides in the hPTH Sequence
 : NUMBER OF SEQUENCES: 36
 : CORRESPONDENCE ADDRESS:
 : ADDRESS: Jones & Askew, LLC
 : STREET: 191 Peachtree Street, 17th Floor
 : CITY: Atlanta
 : STATE: Georgia
 : ZIP: 30303
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: floppy disk
 : OPERATING SYSTEM: IBM PC compatible
 : SOFTWARE: Patent In Release #1.0, Version #1.0
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/08/017547A
 : FILING DATE:
 : PRIOR APPLICATION DATA:
 : APPLICATION NUMBER: PCT/US-95/03757
 : FILING DATE: 29 SEPT 1994
 : ATTORNEY/AGENT INFORMATION:
 : NAME: FRANK, ROBERT
 : REGISTRATION NUMBER: 22,174
 : REFERENCE/DOCKET NUMBER: 01/05/95
 : TELECOMMUNICATION INFORMATION:
 : TELEPHONE: 404-817-3799
 : TELEFAX: 404-817-3799
 : IN-SEMI-AN FOR SEQ. IN NO. 15
 : SEQUENCE CHARACTERISTICS:
 : LENGTH: 7 amino acids
 : TYPE: amino acid
 : STRANDEDNESS: unknown
 : MOLECULE TYPE: peptide
 : ANTI-SENSE: no
 : US-08-817-547A-15

Query Match 40.7% Seq. ID: 34, DB 3, Length 7;
 Best Local Similarity 100.0% Pat. No. 1,76+05;
 Mismatches 0; Indels 0; Caps 0;
 07 9 HNS 12
 14 1 HNS 4

RESULT 13
 US-08-748-021-64
 : Sequence 64, Application US/08/748021
 : Patent No. 5817752
 : GENERAL INFORMATION:
 : APPLICANT: YU, LIN
 : TITLE OF INVENTION: CYCLIC PEPTIDES COMPRISING A


```

: TELEX: 706141
: INFORMATION FOR SEQ 1: NO: 64:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 8 amino acids
: TYPE: amino acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: FEATURES:
: NAME/KEY: Mod11_d-s10
: LOCATION: 1
: OTHER INFORMATION: /residues "10 HER"
: OTHER INFORMATION: /features HS
: OTHER INFORMATION: /notes "In queue"
US-09-730-174a-5-237-64

```

```

Query Match      40.7%  Score 24: DB 3: Length 4:
Best Local Similarity 100.0%  Prod No. 1.7e+05:
Matches 4: Conservative 0: 94 matches 0: H.F.I. 0: Gaps 0:

QY 9 HNLG 12
DB 2 HNLG 6

```

```

Search completed: September 21, 2002, 1:49:33
Job time: 192 sec

```


us-09-730-174a-6.closed.rpr

us-09-730-174a-6.closed.rpr

us-09-730-174a-6.closed.rpr

us-09-730-174a-6.closed.rpr

us-09-730-174a-6.closed.rpr

us-09-730-174a-6.closed.rpr

us-09-730-174a-6.closed.rpr

us-09-730-174a-6.closed.rpr

Sequence: 1 AVSHP001 (12)

OM protein: protein search, using the index

Seq. file: 200009241 (12) 15.45% Search: 100% (12) Scores: (with gaps) 41.14 (12.5) 22.544 (6.1) 26.541 (9.1) of hits/sec

Position: 75 (12) 1244 (6)

Position: 61

Sequence: 1 AVSHP001 (12)

Search file: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)

Search: 100009241 (12)



RESULT 15

Q43924
ID Q43924 PRELIMINARY: 197; 9 AA.
AC Q43924 Q43924: 25,020; Q43924: 9 AA.
DI 01 NOV 1996 (TRENCH: 11, 1996) (sequence update)
DI 01 JUN 2001 (TRENCH: 17, 2001) (sequence update)
DE GRA PER EXP EXP (TRENCH: 17, 2001) (FRAGMENT).
GN EXP.
OS Aeromonas faecalis (Aeromonas faecalis).
OC Bacteria: Proteobacteria: gamma subdivision: Aeromonadaceae.
OC Aeromonas.
OX NCBI_taxid: 648;
RN 111
RP SEQUENCE FROM N.A.
RC STRAIN VARIANTS STRAINS:
EX MEDLINE: 97084747; JOMed 833555;
KA Kariyehov A.V., Mordukhovich S.I.
RT "Study of the intergenic xef-oxf region and its application as a
RT simple preliminary test for Aeromonas spp.";
EL FEMS Microbiol. Lett. 147: 195-200 (1996).
DR EMBL: X89444; CAA61431.1;
DR EMBL: X89442; CAA6139.1;
DR EMBL: X89440; CAA6135.1;
DR EMBL: X89443; CAA6141.1;
FT NON_TER 1 1
SQ SEQUENCE 9 AA: 1 39 MW: 785.626 69444472B GR064;

Query Match: 26.0%; Score: 14; DB: 2; Length: 9;
Best Local Similarity: 50.0%; ID: 4; No. 5,66,05;
Matches: 4; Conservative: 1; Mismatches: 3; Gaps: 0;

QY 4 EIOFENL 11
DB 2 EIOFENL 9

Search completed: September 21, 2002, 11:19:09
Job time: 708 sec

[illegible][illegible]

XX		cardiac disorder; mutant*: mutant.
XX		
XX	Bartus Sp.	
XX	Synthetic.	
XX		
XX	Key:	Location/Qualifiers
XX	Misc-difference 3	/note- "wild-type" See substituted by Ala"
XX	Misc-difference 10	/note- "wild-type" Asn substituted by Glu"
XX		
XX	W-22012-427-Al.	
XX		
XX	04-Apoc-Z601.	
XX		
XX	Z6-FER-Z000; 2000W0-US04716.	
XX		
XX	Z6-SEP-1999; 99DS-0156927.	
XX	(GHEO) GEN RESPIRAL CORP.	
XX		
XX	Lindella TJ. Kronenberg HG. Potts JT. Jefferies H.	
XX	WPI: 29C134(4)/36.	
XX		
XX	Novel amino acid encoding polypeptides useful in the treatment of osteoporosis.	
XX		
XX	Example 3; Page 7; 100pp; Encl. 1-3.	
XX		
XX	The present invention provides a number of parathyroid hormone derivatives based on the rat and human hormone sequences. These peptides can be used in the treatment of human skeletal conditions, including osteoporosis, fractures and calcium disorders, disruption of calcium homeostasis, which may cause severe bone disease, anaemia, renal insufficiency, muscle myopathy and neuropathy, hypocalcaemia and hyperparathyroidism. The present peptide was used in the exemplification of the invention.	
XX	More: the present sequence is not shown in the specification but is derived from the wild type rat parathyroid hormone derivative shown in Example 2 (see AA866896).	
XX		
XX	Sequence: 10 AA;	
XX		
XX	Query Match: 59.0%; Entry 36; DB 22; Length 10;	
XX	Best Local Similarity: 77.8%; Ref. No. 214;	
XX	Match: 7; Conservative: 1; Mismatches: 3; Indels: 0; Gaps: 0;	
XX		
XX	1 AVSRSLGHMH 9	
XX		
XX	1 AVALQGLH 9	
XX		
XX	RES:01_14	
XX	AAR64770	
XX	AA6477) standard; Peptide: 1 AA.	
XX		
XX	AA864770;	
XX		
XX	Z6-JUN-2001 (first entry)	
XX		
XX	parathyroid hormone derivative #11.	
XX		
XX	osteopathic; calcium homeostasis regulator; parathyroid hormone; PTH;	
XX	bone mass; osteoporosis.	
XX		
XX	identified.	
XX		
XX	Key:	Location/Qualifiers
XX	Modified site 11	/note- "optical C-terminal amide"
XX		

1 SCREEN: 115 NUMBER: 1000-4000
 2 CITY: ARLINGTON
 3 STATE: VIRGINIA
 4 COUNTRY: U.S.A.
 5 ZIP: 22201-4114
 6 MEDIUM REPRODUCIBLE FORM:
 7 MEDIUM TYPE: 115 COMPATIBLE
 8 COMPUTER: IBM COMPATIBLE
 9 OPERATING SYSTEM: DOS/MS-DOS
 10 SOFTWARE: PATENT SOFTWARE FOR PROVISION #1.27
 11 CURRENT APPLICATION DATA:
 12 APPLICATION NUMBER: 05/0240-000
 13 FILING DATE: 07-11-95
 14 CLASSIFICATION:
 15 INFORMATION IN INTERNAL:
 16 TELEPHONE: (703) 541-4100
 17 TELEFAX: (703) 541-4100
 18 INFORMATION FOR SEQ. ID NO: 1:
 19 SEQUENCE CHARACTERISTICS:
 20 LENGTH: 10 amino acids
 21 TYPE: amino acid
 22 TOPOLOGY: linear
 23 M-DEGREE TYPE: peptide
 24 US-09-730-174a-6-1

Query Match: 41.0% Seq. ID No: 20 DB 3: Length 10:
 Best Local Similarity: 44.4% Field No: 62:
 Matches: 4: Conservative 2: Mismatches 4: Indels 0: Gaps 0:
 QY 1 AVSEIQPMH 9
 DB 2 ASSEVNYMH 10

RESULT 11
 US-09-730-174a-6-1
 1 Sequence: 115, Application: 05/0240-000
 2 Patent No: 6018042
 3 GENERAL INFORMATION:
 4 APPLICANT: KIRK, Masamichi
 5 APPLICANT: KIRK, Masamichi
 6 APPLICANT: KIRK, Masamichi
 7 APPLICANT: KIRK, Masamichi
 8 APPLICANT: KIRK, Masamichi
 9 APPLICANT: KIRK, Masamichi
 10 APPLICANT: KIRK, Masamichi
 11 APPLICANT: KIRK, Masamichi
 12 APPLICANT: KIRK, Masamichi
 13 APPLICANT: KIRK, Masamichi
 14 APPLICANT: KIRK, Masamichi
 15 APPLICANT: KIRK, Masamichi
 16 APPLICANT: KIRK, Masamichi
 17 APPLICANT: KIRK, Masamichi
 18 APPLICANT: KIRK, Masamichi
 19 APPLICANT: KIRK, Masamichi
 20 APPLICANT: KIRK, Masamichi
 21 APPLICANT: KIRK, Masamichi
 22 APPLICANT: KIRK, Masamichi
 23 APPLICANT: KIRK, Masamichi
 24 APPLICANT: KIRK, Masamichi
 25 APPLICANT: KIRK, Masamichi
 26 APPLICANT: KIRK, Masamichi
 27 APPLICANT: KIRK, Masamichi
 28 APPLICANT: KIRK, Masamichi
 29 APPLICANT: KIRK, Masamichi
 30 APPLICANT: KIRK, Masamichi
 31 APPLICANT: KIRK, Masamichi
 32 APPLICANT: KIRK, Masamichi
 33 APPLICANT: KIRK, Masamichi
 34 APPLICANT: KIRK, Masamichi
 35 APPLICANT: KIRK, Masamichi
 36 APPLICANT: KIRK, Masamichi
 37 APPLICANT: KIRK, Masamichi
 38 APPLICANT: KIRK, Masamichi
 39 APPLICANT: KIRK, Masamichi
 40 APPLICANT: KIRK, Masamichi
 41 APPLICANT: KIRK, Masamichi
 42 APPLICANT: KIRK, Masamichi
 43 APPLICANT: KIRK, Masamichi
 44 APPLICANT: KIRK, Masamichi
 45 APPLICANT: KIRK, Masamichi
 46 APPLICANT: KIRK, Masamichi
 47 APPLICANT: KIRK, Masamichi
 48 APPLICANT: KIRK, Masamichi
 49 APPLICANT: KIRK, Masamichi
 50 APPLICANT: KIRK, Masamichi
 51 APPLICANT: KIRK, Masamichi
 52 APPLICANT: KIRK, Masamichi
 53 APPLICANT: KIRK, Masamichi
 54 APPLICANT: KIRK, Masamichi
 55 APPLICANT: KIRK, Masamichi
 56 APPLICANT: KIRK, Masamichi
 57 APPLICANT: KIRK, Masamichi
 58 APPLICANT: KIRK, Masamichi
 59 APPLICANT: KIRK, Masamichi
 60 APPLICANT: KIRK, Masamichi
 61 APPLICANT: KIRK, Masamichi
 62 APPLICANT: KIRK, Masamichi
 63 APPLICANT: KIRK, Masamichi
 64 APPLICANT: KIRK, Masamichi
 65 APPLICANT: KIRK, Masamichi
 66 APPLICANT: KIRK, Masamichi
 67 APPLICANT: KIRK, Masamichi
 68 APPLICANT: KIRK, Masamichi
 69 APPLICANT: KIRK, Masamichi
 70 APPLICANT: KIRK, Masamichi
 71 APPLICANT: KIRK, Masamichi
 72 APPLICANT: KIRK, Masamichi
 73 APPLICANT: KIRK, Masamichi
 74 APPLICANT: KIRK, Masamichi
 75 APPLICANT: KIRK, Masamichi
 76 APPLICANT: KIRK, Masamichi
 77 APPLICANT: KIRK, Masamichi
 78 APPLICANT: KIRK, Masamichi
 79 APPLICANT: KIRK, Masamichi
 80 APPLICANT: KIRK, Masamichi
 81 APPLICANT: KIRK, Masamichi
 82 APPLICANT: KIRK, Masamichi
 83 APPLICANT: KIRK, Masamichi
 84 APPLICANT: KIRK, Masamichi
 85 APPLICANT: KIRK, Masamichi
 86 APPLICANT: KIRK, Masamichi
 87 APPLICANT: KIRK, Masamichi
 88 APPLICANT: KIRK, Masamichi
 89 APPLICANT: KIRK, Masamichi
 90 APPLICANT: KIRK, Masamichi
 91 APPLICANT: KIRK, Masamichi
 92 APPLICANT: KIRK, Masamichi
 93 APPLICANT: KIRK, Masamichi
 94 APPLICANT: KIRK, Masamichi
 95 APPLICANT: KIRK, Masamichi
 96 APPLICANT: KIRK, Masamichi
 97 APPLICANT: KIRK, Masamichi
 98 APPLICANT: KIRK, Masamichi
 99 APPLICANT: KIRK, Masamichi
 100 APPLICANT: KIRK, Masamichi

1 REFERENCE/DOCKET NUMBER: 150-100
 2 TITLE: INFORMATION IN INTERNAL:
 3 TELEPHONE: 610-270-5096
 4 TELEFAX:
 5 MEDIUM REPRODUCIBLE FORM:
 6 MEDIUM TYPE: 115 COMPATIBLE
 7 COMPUTER: IBM COMPATIBLE
 8 OPERATING SYSTEM: DOS
 9 SOFTWARE: PATENT SOFTWARE FOR PROVISION #1.27
 10 CURRENT APPLICATION DATA:
 11 APPLICATION NUMBER: 05/0240-000
 12 FILING DATE: 07-11-95
 13 CLASSIFICATION:
 14 INFORMATION IN INTERNAL:
 15 TELEPHONE: (703) 541-4100
 16 TELEFAX: (703) 541-4100
 17 INFORMATION FOR SEQ. ID NO: 1:
 18 SEQUENCE CHARACTERISTICS:
 19 LENGTH: 10 amino acids
 20 TYPE: amino acid
 21 TOPOLOGY: linear
 22 M-DEGREE TYPE: peptide
 23 US-09-730-174a-6-1

Query Match: 41.0% Seq. ID No: 20 DB 3: Length 10:
 Best Local Similarity: 44.4% Field No: 62:
 Matches: 4: Conservative 2: Mismatches 4: Indels 0: Gaps 0:
 QY 1 AVSEIQPMH 9
 DB 2 ASSEVNYMH 10

RESULT 12
 US-09-730-174a-6-1
 1 Sequence: 115, Application: 05/0240-000
 2 Patent No: 6018042
 3 GENERAL INFORMATION:
 4 APPLICANT: KIRK, Masamichi
 5 APPLICANT: KIRK, Masamichi
 6 APPLICANT: KIRK, Masamichi
 7 APPLICANT: KIRK, Masamichi
 8 APPLICANT: KIRK, Masamichi
 9 APPLICANT: KIRK, Masamichi
 10 APPLICANT: KIRK, Masamichi
 11 APPLICANT: KIRK, Masamichi
 12 APPLICANT: KIRK, Masamichi
 13 APPLICANT: KIRK, Masamichi
 14 APPLICANT: KIRK, Masamichi
 15 APPLICANT: KIRK, Masamichi
 16 APPLICANT: KIRK, Masamichi
 17 APPLICANT: KIRK, Masamichi
 18 APPLICANT: KIRK, Masamichi
 19 APPLICANT: KIRK, Masamichi
 20 APPLICANT: KIRK, Masamichi
 21 APPLICANT: KIRK, Masamichi
 22 APPLICANT: KIRK, Masamichi
 23 APPLICANT: KIRK, Masamichi
 24 APPLICANT: KIRK, Masamichi
 25 APPLICANT: KIRK, Masamichi
 26 APPLICANT: KIRK, Masamichi
 27 APPLICANT: KIRK, Masamichi
 28 APPLICANT: KIRK, Masamichi
 29 APPLICANT: KIRK, Masamichi
 30 APPLICANT: KIRK, Masamichi
 31 APPLICANT: KIRK, Masamichi
 32 APPLICANT: KIRK, Masamichi
 33 APPLICANT: KIRK, Masamichi
 34 APPLICANT: KIRK, Masamichi
 35 APPLICANT: KIRK, Masamichi
 36 APPLICANT: KIRK, Masamichi
 37 APPLICANT: KIRK, Masamichi
 38 APPLICANT: KIRK, Masamichi
 39 APPLICANT: KIRK, Masamichi
 40 APPLICANT: KIRK, Masamichi
 41 APPLICANT: KIRK, Masamichi
 42 APPLICANT: KIRK, Masamichi
 43 APPLICANT: KIRK, Masamichi
 44 APPLICANT: KIRK, Masamichi
 45 APPLICANT: KIRK, Masamichi
 46 APPLICANT: KIRK, Masamichi
 47 APPLICANT: KIRK, Masamichi
 48 APPLICANT: KIRK, Masamichi
 49 APPLICANT: KIRK, Masamichi
 50 APPLICANT: KIRK, Masamichi
 51 APPLICANT: KIRK, Masamichi
 52 APPLICANT: KIRK, Masamichi
 53 APPLICANT: KIRK, Masamichi
 54 APPLICANT: KIRK, Masamichi
 55 APPLICANT: KIRK, Masamichi
 56 APPLICANT: KIRK, Masamichi
 57 APPLICANT: KIRK, Masamichi
 58 APPLICANT: KIRK, Masamichi
 59 APPLICANT: KIRK, Masamichi
 60 APPLICANT: KIRK, Masamichi
 61 APPLICANT: KIRK, Masamichi
 62 APPLICANT: KIRK, Masamichi
 63 APPLICANT: KIRK, Masamichi
 64 APPLICANT: KIRK, Masamichi
 65 APPLICANT: KIRK, Masamichi
 66 APPLICANT: KIRK, Masamichi
 67 APPLICANT: KIRK, Masamichi
 68 APPLICANT: KIRK, Masamichi
 69 APPLICANT: KIRK, Masamichi
 70 APPLICANT: KIRK, Masamichi
 71 APPLICANT: KIRK, Masamichi
 72 APPLICANT: KIRK, Masamichi
 73 APPLICANT: KIRK, Masamichi
 74 APPLICANT: KIRK, Masamichi
 75 APPLICANT: KIRK, Masamichi
 76 APPLICANT: KIRK, Masamichi
 77 APPLICANT: KIRK, Masamichi
 78 APPLICANT: KIRK, Masamichi
 79 APPLICANT: KIRK, Masamichi
 80 APPLICANT: KIRK, Masamichi
 81 APPLICANT: KIRK, Masamichi
 82 APPLICANT: KIRK, Masamichi
 83 APPLICANT: KIRK, Masamichi
 84 APPLICANT: KIRK, Masamichi
 85 APPLICANT: KIRK, Masamichi
 86 APPLICANT: KIRK, Masamichi
 87 APPLICANT: KIRK, Masamichi
 88 APPLICANT: KIRK, Masamichi
 89 APPLICANT: KIRK, Masamichi
 90 APPLICANT: KIRK, Masamichi
 91 APPLICANT: KIRK, Masamichi
 92 APPLICANT: KIRK, Masamichi
 93 APPLICANT: KIRK, Masamichi
 94 APPLICANT: KIRK, Masamichi
 95 APPLICANT: KIRK, Masamichi
 96 APPLICANT: KIRK, Masamichi
 97 APPLICANT: KIRK, Masamichi
 98 APPLICANT: KIRK, Masamichi
 99 APPLICANT: KIRK, Masamichi
 100 APPLICANT: KIRK, Masamichi

Query Match: 49.86% Score: 40.00 DB: 20 Length: 10
Best Seed: 100.00% Pref: 1.70005
Mat Pos: 50.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

27 0.00000000
10. 1.00000000

Search completed: September 21, 2002, 10:09:33
Job ID: 1001192

